<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>MYCOPHENOLIC ACID- mycophenolate sodiumÂ tablet, delayed releaseÂ </strong><br>American Health Packaging<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use mycophenolic acid delayed-release tablets safely and effectively. See full prescribing information for mycophenolic acid delayed-release tablets.<br><br>MYCOPHENOLIC ACID delayed-release tablets, for oral use <br>Initial U.S. Approval: 2004<br>
</div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: EMBRYOFETAL TOXICITY, MALIGNANCIES, AND SERIOUS <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">INFECTIONS</span></h1>
<h1 class="Warning"><span class="Bold"><span class="Italics">See full prescribing information for complete boxed warning</span></span></h1>
<dl>
<dt>â€¢</dt>
<dd><span class="Bold">Use during pregnancy is associated with increased risks of pregnancy loss and congenital malformations. Females of reproductive potential must be counseled regarding pregnancy prevention and planning. (<a href="#_37fc93c3-2aba-fe53-92ff-fdaeae47308a">5.1</a>, <a href="#_4490778e-3820-1fbc-811d-87881d955316">8.1</a>, <a href="#_a046b033-ca5e-1320-23ac-a01817599255">8.6</a>)</span></dd>
<dt>â€¢</dt>
<dd><span class="Bold">Increased risk of development of <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> and other malignancies, particularly of the skin, due to <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span>. (<a href="#_ed06f621-44e8-4b42-883f-a48f07dae667">5.4</a>)</span></dd>
<dt>â€¢</dt>
<dd><span class="Bold">Increased susceptibility to bacterial, viral, fungal, and protozoal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, including <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span>. (<a href="#_cc4ddf66-d669-608e-8287-64fed7c1ccfb">5.5</a>, <a href="#_25f42243-5613-f581-3853-781a818efbba">5.6</a>) </span></dd>
<dt>â€¢</dt>
<dd><span class="Bold">Only physicians experienced in immunosuppressive therapy and management of organ transplant patients should prescribe mycophenolic acid delayed-release tablets. (<a href="#_5d7d156c-1a7e-03ee-f519-1bebca696d03">5.3</a>)</span></dd>
</dl>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><p class="Highlighta">Warnings and Precautions, New or Reactivated <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">Viral Infections</span> (<a href="#_25f42243-5613-f581-3853-781a818efbba">5.6</a>) Â Â Â Â Â Â 9/2013 </p></div>
</div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: EMBRYOFETAL TOXICITY, MALIGNANCIES, AND SERIOUS <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">INFECTIONS</span></h1>
<h1 class="Warning"><span class="Bold"><span class="Italics">See full prescribing information for complete boxed warning</span></span></h1>
<dl>
<dt>â€¢</dt>
<dd><span class="Bold">Use during pregnancy is associated with increased risks of pregnancy loss and congenital malformations. Females of reproductive potential must be counseled regarding pregnancy prevention and planning. (<a href="#_37fc93c3-2aba-fe53-92ff-fdaeae47308a">5.1</a>, <a href="#_4490778e-3820-1fbc-811d-87881d955316">8.1</a>, <a href="#_a046b033-ca5e-1320-23ac-a01817599255">8.6</a>)</span></dd>
<dt>â€¢</dt>
<dd><span class="Bold">Increased risk of development of <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> and other malignancies, particularly of the skin, due to <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span>. (<a href="#_ed06f621-44e8-4b42-883f-a48f07dae667">5.4</a>)</span></dd>
<dt>â€¢</dt>
<dd><span class="Bold">Increased susceptibility to bacterial, viral, fungal, and protozoal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, including <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span>. (<a href="#_cc4ddf66-d669-608e-8287-64fed7c1ccfb">5.5</a>, <a href="#_25f42243-5613-f581-3853-781a818efbba">5.6</a>) </span></dd>
<dt>â€¢</dt>
<dd><span class="Bold">Only physicians experienced in immunosuppressive therapy and management of organ transplant patients should prescribe mycophenolic acid delayed-release tablets. (<a href="#_5d7d156c-1a7e-03ee-f519-1bebca696d03">5.3</a>)</span></dd>
</dl>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<dl>
<dt>â€¢</dt>
<dd>Mycophenolic acid delayed-release tablets are an antimetabolite immunosuppressant indicated for prophylaxis of organ rejection in adult patients receiving kidney transplants and in pediatric patients at least 5 years of age and older who are at least 6 months post kidney transplant. (<a href="#_06d4b90e-49c8-37c1-3b1d-951eb668c63e">1.1</a>)</dd>
<dt>â€¢</dt>
<dd>Use in combination with cyclosporine and corticosteroids. (<a href="#_06d4b90e-49c8-37c1-3b1d-951eb668c63e">1.1</a>) </dd>
</dl>
<p class="Highlighta">Â  Limitations of Use: </p>
<dl>
<dt>â€¢</dt>
<dd>Mycophenolic acid delayed-release tablets and mycophenolate mofetil tablets and capsules should not be used interchangeably. (<a href="#_4b7d9506-d670-d58a-bf53-d134ec1a9dfd">1.2</a>)</dd>
</dl>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>In adults: 720 mg by mouth, twice daily (1440 mg total daily dose) on an empty stomach, 1 hour before or 2 hours after food intake. (<a href="#_9add5ca3-9d8a-b4c2-bc27-5eda9f9540d5">2.1</a>)</dd>
<dt>â€¢</dt>
<dd>In children: 5 years of age and older (who are at least 6 months post kidney transplant), 400 mg/m<span class="Sup">2</span> by mouth, twice daily (up to a maximum of 720 mg twice daily). (<a href="#_6174dd6a-75fc-9084-fe51-d1997a955536">2.2</a>)</dd>
<dt>â€¢</dt>
<dd>Do not crush, chew, or cut tablet prior to ingestion. (<a href="#_63836cf5-69e1-327a-5aa1-2efa96de1c9e">2.3</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Mycophenolic acid is available as 180 mg and 360 mg tablets. (<a href="#_bbe079a3-65a7-51dd-4b04-959de2322fb0">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to mycophenolate sodium, mycophenolic acid, mycophenolate mofetil, or to any of its excipients. (<a href="#_2b7b602a-b519-6d1d-e9a9-c90db97735a7">4.1</a>) </p></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>New or Reactivated <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">Viral Infections</span>: Consider reducing <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span>. (<a href="#_25f42243-5613-f581-3853-781a818efbba">5.6</a>)</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">Blood Dyscrasias</span> including Pure <span class="product-label-link" type="condition" conceptid="4226622" conceptname="Decreased erythroid precursor production">Red Cell Aplasia</span> (PRCA): Monitor for <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> or <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>; consider treatment interruption or dose reduction. (<a href="#_Ref">5.7</a>)</dd>
<dt>â€¢</dt>
<dd>Serious GI Tract Complications (<span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span>, perforations and <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span>): Administer with caution to patients with active digestive system disease. (<a href="#_62addb2f-e8ac-b84b-a759-9a461e2cb7b5">5.8</a>)</dd>
<dt>â€¢</dt>
<dd>Immunizations: Avoid live vaccines. (<a href="#_dfa6ce1f-c95f-519b-a3c7-f7eb50619701">5.9</a>)</dd>
<dt>â€¢</dt>
<dd>Patients with Hereditary Deficiency of Hypoxanthine-guanine Phosphoribosyl-transferase (HGPRT): May cause exacerbation of disease symptoms; avoid use. (<a href="#_5600c5d2-d10b-f30d-65b2-72be4c9c5bb3">5.10</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div><p class="Highlighta">Most common adverse reactions (â‰¥ 20%): <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>, <span class="product-label-link" type="condition" conceptid="440032" conceptname="Cytomegalovirus infection">CMV infection</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, and <span class="product-label-link" type="condition" conceptid="439502" conceptname="Postoperative pain">postoperative pain</span>. (<a href="#_e279f1e1-4aea-cc59-5149-3087a3d8c1dc">6.2</a>)<br><br><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Apotex Corp. at 1-800-706-5575 or FDA at 1-800-FDA-1088 or <span class="Italics"><span class="Underline">www.fda.gov/medwatch</span></span>.</span> </p></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Antacids with magnesium and aluminum hydroxides: Decreases concentrations of mycophenolic acid (MPA); concomitant use is not recommended. (<a href="#_25006cf6-1a0f-5270-85c9-5f51338f89e7">7.1</a>)</dd>
<dt>â€¢</dt>
<dd>Azathioprine: Competition for purine metabolism; concomitant administration is not recommended. (<a href="#_e30e36fa-0828-bf14-eac9-c65a8d5caa03">7.2</a>)</dd>
<dt>â€¢</dt>
<dd>Cholestyramine, Bile Acid Sequestrates, Oral Activated Charcoal, and Other Drugs that Interfere with Enterohepatic Recirculation: May decrease MPA concentrations; concomitant use is not recommended. (<a href="#_e1c43148-2bb3-d3ad-39be-55904c38d8fb">7.3</a>)</dd>
<dt>â€¢</dt>
<dd>Sevelamer: May decrease MPA concentrations; concomitant use is not recommended. (<a href="#_1d408f0b-ef8a-3835-996c-b330d3d76c1c">7.4</a>)</dd>
<dt>â€¢</dt>
<dd>Cyclosporine: May decrease MPA concentrations; exercise caution when switching from cyclosporine to other drugs or from other drugs to cyclosporine. (<a href="#_550160ee-23c3-c859-157a-29118cae59a3">7.5</a>)</dd>
<dt>â€¢</dt>
<dd>Norfloxacin and Metronidazole: May decrease MPA concentrations; concomitant use with both drugs is not recommended. (<a href="#_3a22776d-4fc3-cee7-9508-924ac05af8af">7.6</a>)</dd>
<dt>â€¢</dt>
<dd>Rifampin: May decrease MPA concentrations; concomitant use is not recommended unless the benefit outweighs the risk. (<a href="#_cdc89a6c-1452-0190-1919-0b347922db7e">7.7</a>)</dd>
<dt>â€¢</dt>
<dd>Hormonal Contraceptives: Additional barrier contraceptive methods must be used. (<a href="#_91d0387f-1afc-3a3a-3ace-f50b8d7f5af3">5.2</a>, <a href="#_805e298a-5962-9447-592c-6f80bf8d81c7">7.8</a>)</dd>
<dt>â€¢</dt>
<dd>Acyclovir, Valacyclovir, Ganciclovir, Valganciclovir, and other drugs that undergo renal tubular secretion: May increase concentrations of mycophenolic acid glucuronide (MPAG) and coadministered drug; monitor blood cell counts. (<a href="#_957caeb9-5f1b-7887-8cb1-2b72175e20aa">7.9</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Pregnancy: Can cause fetal harm. (<a href="#_37fc93c3-2aba-fe53-92ff-fdaeae47308a">5.1</a>, <a href="#_4490778e-3820-1fbc-811d-87881d955316">8.1</a>)</dd>
<dt>â€¢</dt>
<dd>Nursing Mothers: Discontinue drug or discontinue nursing while on treatment or within 6 weeks after stopping therapy, taking into consideration the importance of the drug to the mother. (<a href="#_69a7ec3a-0a4a-afff-b845-11e7a6e7e93e">8.3</a>)</dd>
<dt>â€¢</dt>
<dd>Females of reproductive potential must be counseled regarding pregnancy prevention and planning. (<a href="#_91d0387f-1afc-3a3a-3ace-f50b8d7f5af3">5.2</a>,<a href="#_a046b033-ca5e-1320-23ac-a01817599255"> 8.6</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div><div></div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 2/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">WARNING: EMBRYOFETAL TOXICITY, MALIGNANCIES, AND SERIOUS <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">INFECTIONS</span></a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE </a></h1>
<h2><a href="#section-1.1" class="toc"> 1.1 Prophylaxis of Organ Rejection in Kidney Transplant </a></h2>
<h2><a href="#section-1.2" class="toc">1.2 Limitations of Use</a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION </a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Dosage in Adult Kidney Transplant Patients</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Dosage in Pediatric Kidney Transplant Patients </a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Administration</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS </a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS </a></h1>
<h2><a href="#section-4.1" class="toc">4.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></a></h2>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS </a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Embryofetal Toxicity</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Pregnancy Exposure Prevention and Planning</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Management of <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">Immunosuppression</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4 <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span> and Other Malignancies</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6 New or Reactivated <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">Viral Infections</span></a></h2>
<h2><a href="#section-5.7" class="toc">5.7 <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">Blood Dyscrasias</span> Including Pure <span class="product-label-link" type="condition" conceptid="4226622" conceptname="Decreased erythroid precursor production">Red Cell Aplasia</span></a></h2>
<h2><a href="#section-5.8" class="toc">5.8 Serious GI Tract Complications</a></h2>
<h2><a href="#section-5.9" class="toc">5.9 Immunizations</a></h2>
<h2><a href="#section-5.10" class="toc">5.10 Rare Hereditary Deficiencies</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Studies Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS </a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Antacids with Magnesium and Aluminum Hydroxides</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Azathioprine</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Cholestyramine, Bile Acid Sequestrates, Oral Activated Charcoal and Other Drugs that Interfere with Enterohepatic Recirculation</a></h2>
<h2><a href="#section-7.4" class="toc">7.4Â  Sevelamer</a></h2>
<h2><a href="#section-7.5" class="toc">7.5 Cyclosporine</a></h2>
<h2><a href="#section-7.6" class="toc">7.6 Norfloxacin and Metronidazole</a></h2>
<h2><a href="#section-7.7" class="toc">7.7 Rifampin</a></h2>
<h2><a href="#section-7.8" class="toc">7.8 Hormonal Contraceptives</a></h2>
<h2><a href="#section-7.9" class="toc">7.9 Acyclovir (Valacyclovir), Ganciclovir (Valganciclovir), and Other Drugs that Undergo Renal Tubular Secretion</a></h2>
<h2><a href="#section-7.10" class="toc">7.10 Ciprofloxacin, Amoxicillin plus Clavulanic Acid and Other Drugs that Alter the Gastrointestinal Flora</a></h2>
<h2><a href="#section-7.11" class="toc">7.11Â Pantoprazole</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 Females of Reproductive Potential Pregnancy Exposure Prevention and Planning  </a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE </a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES </a></h1>
<h2><a href="#section-13.1" class="toc">14. 1 Prophylaxis of Organ Rejection in Patients Receiving Allogeneic Renal Transplants</a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="ID_f2a1f195-2afd-4f28-b2a3-0ec88a43595c"></a><a name="section-1"></a><p></p>
<h1>WARNING: EMBRYOFETAL TOXICITY, MALIGNANCIES, AND SERIOUS <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">INFECTIONS</span></h1>
<dl>
<dt>â€¢</dt>
<dd><span class="Bold">Use during pregnancy is associated with increased risks of pregnancy loss and congenital malformations. Females of reproductive potential must be counseled regarding pregnancy prevention and planning [see <span class="Italics">Warnings and Precautions (<a href="#_37fc93c3-2aba-fe53-92ff-fdaeae47308a">5.1</a>)</span>, <span class="Italics">Use in Specific Populations (<a href="#_4490778e-3820-1fbc-811d-87881d955316">8.1</a>, <a href="#_a046b033-ca5e-1320-23ac-a01817599255">8.6</a>)</span>].</span></dd>
<dt>â€¢</dt>
<dd><span class="Bold">Increased risk of development of <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> and other malignancies, particularly of the skin, due to <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> [see <span class="Italics">Warnings and Precautions (<a href="#_ed06f621-44e8-4b42-883f-a48f07dae667">5.4</a>)</span>]. </span></dd>
<dt>â€¢</dt>
<dd><span class="Bold">Increased susceptibility to bacterial, viral, fungal, and protozoal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, including <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span> [see <span class="Italics">Warnings and Precautions (<a href="#_cc4ddf66-d669-608e-8287-64fed7c1ccfb">5.5</a>, <a href="#_25f42243-5613-f581-3853-781a818efbba">5.6</a>)</span>]. </span></dd>
<dt>â€¢</dt>
<dd><span class="Bold">Only physicians experienced in immunosuppressive therapy and management of organ transplant patients should prescribe mycophenolic acid. Patients receiving mycophenolic acid should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources. The physician responsible for maintenance therapy should have complete information requisite for the follow-up of the patient [see <span class="Italics">Warnings and Precautions (<a href="#_5d7d156c-1a7e-03ee-f519-1bebca696d03">5.3</a>)</span>].</span></dd>
</dl>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="_47e8dfa6-5374-8d0f-0c2e-f58db5d150ea"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE </h1>
<div class="Section" data-sectionCode="42229-5">
<a name="_06d4b90e-49c8-37c1-3b1d-951eb668c63e"></a><a name="section-1.1"></a><p></p>
<h2> 1.1 Prophylaxis of Organ Rejection in Kidney Transplant </h2>
<p class="First">Mycophenolic acid is indicated for the prophylaxis of organ rejection in adult patients receiving a kidney transplant.Â </p>
<p>Mycophenolic acid is indicated for the prophylaxis of organ rejection in pediatric patients 5 years of age and older who are at least 6 months post kidney transplant.Â </p>
<p>Mycophenolic acid is to be used in combination with cyclosporine and corticosteroids.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_4b7d9506-d670-d58a-bf53-d134ec1a9dfd"></a><a name="section-1.2"></a><p></p>
<h2>1.2 Limitations of Use</h2>
<p class="First">Mycophenolic acid delayed-release tablets and mycophenolate mofetil (MMF) tablets and capsules should not be used interchangeably without physician supervision because the rate of absorption following the administration of these two products is not equivalent.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="_782bb39b-cc2b-547d-4315-8ce4cd4b4f2e"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION </h1>
<div class="Section" data-sectionCode="42229-5">
<a name="_9add5ca3-9d8a-b4c2-bc27-5eda9f9540d5"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Dosage in Adult Kidney Transplant Patients</h2>
<p class="First">The recommended dose of mycophenolic acid delayed-release tablets is 720 mg administered twice daily (1440 mg total daily dose).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_6174dd6a-75fc-9084-fe51-d1997a955536"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Dosage in Pediatric Kidney Transplant Patients </h2>
<p class="First">The recommended dose of mycophenolic acid in conversion (at least 6 months post-transplant) pediatric patients age 5 years and older is 400 mg/m<span class="Sup">2</span> body surface area (BSA) administered twice daily (up to a maximum dose of 720 mg administered twice daily).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_63836cf5-69e1-327a-5aa1-2efa96de1c9e"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Administration</h2>
<p class="First">Mycophenolic acid delayed-release tablets should be taken on an empty stomach, 1 hour before or 2 hours after food intake [see <span class="Italics">Clinical Pharmacology (<a href="#_bb3d86be-45ce-556a-7931-10efd63f972f">12.3</a>)</span>].Â </p>
<p>Mycophenolic acid delayed-release tablets should not be crushed, chewed, or cut prior to ingesting. The tablets should be swallowed whole in order to maintain the integrity of the enteric coating.Â </p>
<p>Pediatric patients with a BSA of 1.19 to 1.58 m<span class="Sup">2</span> may be dosed either with three mycophenolic acid 180 mg tablets, or one 180 mg tablet plus one 360 mg tablet twice daily (1080 mg daily dose). Patients with a BSA of &gt;1.58 m<span class="Sup">2</span> may be dosed either with four mycophenolic acid 180 mg tablets, or two mycophenolic acid 360 mg tablets twice daily (1440 mg daily dose). Pediatric doses for patients with BSA &lt;1.19 m<span class="Sup">2</span> cannot be accurately administered using currently available formulations of mycophenolic acid tablets.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="_bbe079a3-65a7-51dd-4b04-959de2322fb0"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS </h1>
<p class="First">Mycophenolic acid delayed-release tablets are available as 180 mg and 360 mg tablets.Â </p>
<p><span class="Bold">Table 1: Description of Mycophenolic Acid Delayed-Release Tablets</span></p>
<table cellpadding="0pt" cellspacing="0pt" width="100%">
<col width="33%">
<col width="33%">
<col width="33%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule Toprule"><p class="First"><span class="Bold">Dosage Strength</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">180 mg tablet</span></p></td>
<td class="Botrule Lrule Toprule"><p class="First"><span class="Bold">360 mg tablet</span></p></td>
</tr>
<tr>
<td class="Botrule Rrule Toprule"><p class="First">Active ingredient</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">mycophenolic acid as mycophenolate sodium</p></td>
<td class="Botrule Lrule Toprule"><p class="First">mycophenolic acid as mycophenolate sodium</p></td>
</tr>
<tr>
<td class="Botrule Rrule Toprule"><p class="First">Appearance</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Light green, round, slightly biconvex beveled edge enteric coated tablet</p></td>
<td class="Botrule Lrule Toprule"><p class="First">Light pink, oval, biconvex enteric coated tablet</p></td>
</tr>
<tr class="Last">
<td class="Botrule Rrule Toprule"><p class="First">Imprint</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">â€œMYCâ€? over â€œ180â€? on one side, â€œAPOâ€? on the other side</p></td>
<td class="Botrule Lrule Toprule"><p class="First">â€œAPOâ€? on one side, â€œMYC 360â€? on the other side</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="_973b5b0a-cf21-41bd-aeb9-0ef4ec58f23e"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS </h1>
<div class="Section" data-sectionCode="42229-5">
<a name="_2b7b602a-b519-6d1d-e9a9-c90db97735a7"></a><a name="section-4.1"></a><p></p>
<h2>4.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></h2>
<p class="First">Mycophenolic acid delayed-release tablets are contraindicated in patients with a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to mycophenolate sodium, mycophenolic acid, mycophenolate mofetil, or to any of its excipients. Reactions like <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> have been observed in clinical trials and post marketing reports [see <span class="Italics">Adverse Reactions (<a href="#_539f9292-93d9-fcf1-24cc-2353e2cc18f8">6</a>)</span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="_688ff708-800e-3a53-2033-e2a59c529aae"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS </h1>
<div class="Section" data-sectionCode="42229-5">
<a name="_37fc93c3-2aba-fe53-92ff-fdaeae47308a"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Embryofetal Toxicity</h2>
<p class="First">Use of mycophenolic acid delayed-release tablets during pregnancy is associated with an increased risk of first trimester pregnancy loss and an increased risk of congenital malformations, especially external ear and other facial abnormalities including <span class="product-label-link" type="condition" conceptid="134144" conceptname="Cleft palate with cleft lip">cleft lip and palate</span>, and anomalies of the distal limbs, heart, esophagus, and kidney [see <span class="Italics">Use in Specific Populations (<a href="#_4490778e-3820-1fbc-811d-87881d955316">8.1</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_91d0387f-1afc-3a3a-3ace-f50b8d7f5af3"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Pregnancy Exposure Prevention and Planning</h2>
<p class="First">Females of reproductive potential must be aware of the increased risk of first trimester pregnancy loss and congenital malformations and must be counseled regarding pregnancy prevention and planning. For recommended pregnancy testing and contraception methods [see <span class="Italics">Use in Specific Populations (<a href="#_a046b033-ca5e-1320-23ac-a01817599255">8.6</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_5d7d156c-1a7e-03ee-f519-1bebca696d03"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Management of <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">Immunosuppression</span></h2>
<p class="First">Only physicians experienced in immunosuppressive therapy and management of organ transplant patients should prescribe mycophenolic acid delayed-release tablets. Patients receiving the drug should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources. The physicians responsible for maintenance therapy should have complete information requisite for the follow-up of the patient [see <span class="Italics"><a href="#ID_f2a1f195-2afd-4f28-b2a3-0ec88a43595c">Boxed Warning</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_ed06f621-44e8-4b42-883f-a48f07dae667"></a><a name="section-5.4"></a><p></p>
<h2>5.4 <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span> and Other Malignancies</h2>
<p class="First">Patients receiving immunosuppressants, including mycophenolic acid delayed-release tablets, are at increased risk of developing <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphomas</span> and other malignancies, particularly of the skin [see <span class="Italics">Adverse Reactions (<a href="#_539f9292-93d9-fcf1-24cc-2353e2cc18f8">6</a>)</span>]. The risk appears to be related to the intensity and duration of <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> rather than to the use of any specific agent.Â </p>
<p>As usual for patients with increased risk for skin cancer, exposure to sunlight and UV light should be limited by wearing protective clothing and using a sunscreen with a high protection factor.Â </p>
<p>Post-transplant <span class="product-label-link" type="condition" conceptid="4079147" conceptname="Lymphoproliferative disorder">lymphoproliferative disorder</span> (PTLD) has been reported in immunosuppressed organ transplant recipients. The majority of PTLD events appear related to Epstein Barr Virus (EBV) <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. The risk of PTLD appears greatest in those individuals who are EBV seronegative, a population which includes many young children.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_cc4ddf66-d669-608e-8287-64fed7c1ccfb"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></h2>
<p class="First">Patients receiving immunosuppressants, including mycophenolic acid delayed-release tablets, are at increased risk of developing bacterial, viral, fungal, and protozoal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, and new or reactivated <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> including <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span> [see <span class="Italics">Warnings and Precautions (<a href="#_25f42243-5613-f581-3853-781a818efbba">5.6</a>)</span>]. These <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> may lead to serious, including fatal outcomes. Because of the danger of oversuppression of the immune system which can increase susceptibility to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, combination immunosuppressant therapy should be used with caution.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_25f42243-5613-f581-3853-781a818efbba"></a><a name="section-5.6"></a><p></p>
<h2>5.6 New or Reactivated <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">Viral Infections</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Polyomavirus associated <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">nephropathy</span> (PVAN), JC virus associated <span class="product-label-link" type="condition" conceptid="433957" conceptname="Progressive multifocal leukoencephalopathy">progressive multifocal leukoencephalopathy</span> (PML), cytomegalovirus (CMV) <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, reactivation of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B (HBV) or <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C (HCV) have been reported in patients treated with immunosuppressants, including the mycophenolic acid (MPA) derivatives mycophenolic acid delayed-release tablets and MMF. Reduction in <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> should be considered for patients who develop evidence of new or reactivated <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span>. Physicians should also consider the risk that reduced <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> represents to the functioning allograft. </span></p>
<p>PVAN, especially due to BK virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, is associated with serious outcomes, including deteriorating renal function and renal graft loss. Patient monitoring may help detect patients at risk for PVAN.Â </p>
<p style="border-left:1px solid;"><span class="XmChange">PML, which is sometimes fatal, commonly presents with <span class="product-label-link" type="condition" conceptid="4065756" conceptname="Hemiparesis">hemiparesis</span>, <span class="product-label-link" type="condition" conceptid="4071366" conceptname="Indifference">apathy</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, cognitive deficiencies, and <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>. Risk factors for PML include treatment with immunosuppressant therapies and impairment of immune function. In immunosuppressed patients, physicians should consider PML in the differential diagnosis in patients reporting neurological symptoms and consultation with a neurologist should be considered as clinically indicated.Â </span></p>
<p style="border-left:1px solid;"><span class="XmChange">The risk of <span class="product-label-link" type="condition" conceptid="45757222" conceptname="Cytomegalovirus viraemia">CMV viremia</span> and CMV disease is highest among transplant recipients seronegative for CMV at time of transplant who receive a graft from a CMV seropositive donor. Therapeutic approaches to limiting CMV disease exist and should be routinely provided. Patient monitoring may help detect patients at risk for CMV disease [see <span class="Italics">Adverse Reactions (<a href="#_Ref">6.1</a>)</span>].</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Viral reactivation has been reported in patients infected with HBV or HCV. Monitoring infected patients for clinical and laboratory signs of active HBV or HCV <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> is recommended.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_62addb2f-e8ac-b84b-a759-9a461e2cb7b5"></a><a name="section-5.7"></a><p></p>
<h2>5.7 <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">Blood Dyscrasias</span> Including Pure <span class="product-label-link" type="condition" conceptid="4226622" conceptname="Decreased erythroid precursor production">Red Cell Aplasia</span></h2>
<p class="First">Cases of pure <span class="product-label-link" type="condition" conceptid="4226622" conceptname="Decreased erythroid precursor production">red cell aplasia</span> (PRCA) have been reported in patients treated with MPA derivatives in combination with other immunosuppressive agents. The mechanism for MPA derivatives induced PRCA is unknown; the relative contribution of other immunosuppressants and their combinations in an immunosuppressive regimen is also unknown. In some cases PRCA was found to be reversible with dose reduction or cessation of therapy with MPA derivatives. In transplant patients, however, reduced <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> may place the graft at risk. Changes to mycophenolic acid therapy should only be undertaken under appropriate supervision in transplant recipients in order to minimize the risk of <span class="product-label-link" type="condition" conceptid="4248020" conceptname="Graft rejection">graft rejection</span>.</p>
<p>Patients receiving mycophenolic acid should be monitored for <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood dyscrasias</span> (e.g., <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> or <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>). The development of <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> may be related to mycophenolic acid itself, concomitant medications, <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span>, or some combination of these reactions. Complete blood count should be performed weekly during the first month, twice monthly for the second and the third month of treatment, then monthly through the first year. If <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood dyscrasias</span> occur [<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> develops (ANC &lt;1.3Ã—10<span class="Sup">3</span>/mcL) or <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>], dosing with mycophenolic acid should be interrupted or the dose reduced, appropriate tests performed, and the patient managed accordingly.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_dfa6ce1f-c95f-519b-a3c7-f7eb50619701"></a><a name="section-5.8"></a><p></p>
<h2>5.8 Serious GI Tract Complications</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">Gastrointestinal bleeding</span> (requiring hospitalization), <span class="product-label-link" type="condition" conceptid="193242" conceptname="Perforation of intestine">intestinal perforations</span>, <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcers</span>, and <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcers</span> have been reported in patients treated with mycophenolic acid delayed-release tablets. Mycophenolic acid delayed-release tablets should be administered with caution in patients with active serious digestive system disease.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_5600c5d2-d10b-f30d-65b2-72be4c9c5bb3"></a><a name="section-5.9"></a><p></p>
<h2>5.9 Immunizations</h2>
<p class="First">The use of live attenuated vaccines should be avoided during treatment with mycophenolic acid delayed-release tablets; examples include (but not limited to) the following: intranasal <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>, <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span>, <span class="product-label-link" type="condition" conceptid="4290000" conceptname="Mumps">mumps</span>, <span class="product-label-link" type="condition" conceptid="4273323" conceptname="Rubella">rubella</span>, oral <span class="product-label-link" type="condition" conceptid="136330" conceptname="Acute nonparalytic poliomyelitis">polio</span>, BCG, <span class="product-label-link" type="condition" conceptid="441210" conceptname="Yellow fever">yellow fever</span>, <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span>, and TY21a <span class="product-label-link" type="condition" conceptid="192819" conceptname="Typhoid fever">typhoid</span> vaccines.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_92578e94-a7db-555f-0028-b9e63c67745e"></a><a name="section-5.10"></a><p></p>
<h2>5.10 Rare Hereditary Deficiencies</h2>
<p class="First">Mycophenolic acid is an inosine monophosphate dehydrogenase inhibitor (IMPDH Inhibitor). Mycophenolic acid should be avoided in patients with rare hereditary deficiency of hypoxanthine-guanine phosphoribosyl-transferase (HGPRT) such as Lesch- Nyhan and Kelley-Seegmiller syndromes because it may cause an exacerbation of disease symptoms characterized by the overproduction and accumulation of uric acid leading to symptoms associated with <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span> such as <span class="product-label-link" type="condition" conceptid="4000634" conceptname="Acute arthritis">acute arthritis</span>, tophi, <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">nephrolithiasis</span> or <span class="product-label-link" type="condition" conceptid="79873" conceptname="Urolith">urolithiasis</span> and <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> including <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="_539f9292-93d9-fcf1-24cc-2353e2cc18f8"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following adverse reactions are discussed in greater detail in other sections of the label.</p>
<dl>
<dt>â€¢</dt>
<dd>Embryofetal Toxicity [see <span class="Italics"><a href="#ID_f2a1f195-2afd-4f28-b2a3-0ec88a43595c">Boxed Warning</a>, Warnings and Precautions</span> (<span class="Italics"><a href="#_37fc93c3-2aba-fe53-92ff-fdaeae47308a">5.1</a>)</span>]</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphomas</span> and Other Malignancies [see <span class="Italics"><a href="#ID_f2a1f195-2afd-4f28-b2a3-0ec88a43595c">Boxed Warning</a>, Warnings and Precautions (<a href="#_ed06f621-44e8-4b42-883f-a48f07dae667">5.4</a>)</span>]</dd>
<dt>â€¢</dt>
<dd>Serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> [see <span class="Italics"><a href="#ID_f2a1f195-2afd-4f28-b2a3-0ec88a43595c">Boxed Warning</a>, Warnings and Precautions (<a href="#_cc4ddf66-d669-608e-8287-64fed7c1ccfb">5.5</a>)</span>]</dd>
<dt>â€¢</dt>
<dd>New or Reactivated <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">Viral Infections</span> [see <span class="Italics">Warnings and Precautions (<a href="#_25f42243-5613-f581-3853-781a818efbba">5.6</a>)</span>]</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">Blood Dyscrasias</span> Including Pure <span class="product-label-link" type="condition" conceptid="4226622" conceptname="Decreased erythroid precursor production">Red Cell Aplasia</span> [see <span class="Italics">Warnings and Precautions (<a href="#_62addb2f-e8ac-b84b-a759-9a461e2cb7b5">5.7)</a></span>]</dd>
<dt>â€¢</dt>
<dd>Serious GI Tract Complications [see <span class="Italics">Warnings and Precautions (<a href="#_dfa6ce1f-c95f-519b-a3c7-f7eb50619701">5.8</a>)</span>]</dd>
<dt>â€¢</dt>
<dd>Rare Hereditary Deficiencies [see <span class="Italics">Warnings and Precautions (<a href="#_92578e94-a7db-555f-0028-b9e63c67745e">5.10</a>)</span>]</dd>
</dl>
<div class="Section" data-sectionCode="42229-5">
<a name="_e24c1f38-d21c-e0d2-d38d-39656f12c0d6"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Studies Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>The data described below derive from two randomized, comparative, active-controlled, double-blind, double-dummy trials in prevention of acute rejection in <span class="Italics">de novo</span> and converted stable kidney transplant patients.</p>
<p>In the <span class="Italics">de novo</span> trial, patients were administered either mycophenolic acid delayed-release tablets 1.44 grams per day (N=213) or MMF 2 grams per day (N=210) within 48 hours post-transplant for 12 months in combination with cyclosporine, USP MODIFIED and corticosteroids. Forty-one percent of patients also received antibody therapy as induction treatment. In the conversion trial, renal transplant patients who were at least 6 months post-transplant and receiving 2 grams per day MMF in combination with cyclosporine USP MODIFIED, with or without corticosteroids for at least two weeks prior to entry in the trial were randomized to mycophenolic acid delayed-release tablets 1.44 grams per day (N=159) or MMF 2 grams per day (N=163) for 12 months.</p>
<p>The average age of patients in both studies was 47 years and 48 years (<span class="Italics">de novo</span> study and conversion study, respectively), ranging from 22 to 75 years. Approximately 66% of patients were male; 82% were white, 12% were black, and 6% other races. About 40% of patients were from the United States and 60% from other countries.</p>
<p>In the <span class="Italics">de novo</span> trial, the overall incidence of discontinuation due to adverse reactions was 18% (39/213) and 17% (35/210) in the mycophenolic acid delayed-release tablets and MMF arms, respectively<span class="Italics">. </span>The most common adverse reactions leading to discontinuation in the mycophenolic acid arm were graft loss (2%), <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (2%), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (1%), <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (1%), <span class="product-label-link" type="condition" conceptid="440032" conceptname="Cytomegalovirus infection">CMV infection</span> (1%), and <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> (1%). The overall incidence of patients reporting dose reduction at least once during the 0 to12 month study period was 59% and 60% in the mycophenolic acid delayed-release tablets and MMF arms, respectively. The most frequent reasons for dose reduction in the mycophenolic acid delayed-release tablets arm were adverse reactions (44%), dose reductions according to protocol guidelines (17%), dosing errors (11%) and missing data (2%).</p>
<p>The most common adverse reactions (â‰¥20%) associated with the administration of mycophenolic acid delayed-release tablets were <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>, <span class="product-label-link" type="condition" conceptid="440032" conceptname="Cytomegalovirus infection">CMV infection</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> and <span class="product-label-link" type="condition" conceptid="439502" conceptname="Postoperative pain">postoperative pain</span>.</p>
<p>The adverse reactions reported in â‰¥10% of patients in the <span class="Italics">de novo</span> trial are presented in Table 2 below.</p>
<p><span class="Bold">Table 2: Adverse Reactions (%) Reported in â‰¥10% of <span class="Italics">de novo</span> Kidney Transplant Patients in Either Treatment Group</span></p>
<table cellpadding="0pt" cellspacing="0pt" width="100%">
<col width="38%">
<col width="17%">
<col width="14%">
<col width="13%">
<col width="18%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Toprule"></td>
<td class="Botrule Toprule" align="center" colspan="4"><p class="First"><span class="Bold"><span class="Italics"> de novo </span>Renal Trial</span></p></td>
</tr>
<tr>
<td class="Toprule"><p class="First">System organ class</p></td>
<td class="Toprule" align="center"><p class="First"><span class="Bold">Mycophenolic acid</span><br><span class="Bold"> delayed-release </span><br><span class="Bold">tablets</span></p></td>
<td class="Toprule"></td>
<td class="Toprule"></td>
<td class="Toprule" align="center" valign="middle"><p class="First"><span class="Bold">mycophenolate </span><br><span class="Bold">mofetil <br>(MMF)</span></p></td>
</tr>
<tr>
<td class="Botrule"><p class="First">Adverse drug reactions</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First"><span class="Bold">1.44 grams per day<br>(n=213)</span><br><span class="Bold">%</span></p></td>
<td class="Botrule"></td>
<td class="Botrule"></td>
<td class="Botrule" align="center" valign="middle"><p class="First"><span class="Bold">2 grams per day<br>(n=210)<br>%</span></p></td>
</tr>
<tr><td colspan="5"><p class="First"><span class="Bold">Blood and Lymphatic System Disorders</span></p></td></tr>
<tr>
<td><p class="First">Â Â Â Â <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></p></td>
<td align="center" valign="middle"><p class="First">22</p></td>
<td></td>
<td></td>
<td align="center" valign="middle"><p class="First">22</p></td>
</tr>
<tr>
<td><p class="First">Â Â Â Â <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span></p></td>
<td align="center" valign="middle"><p class="First">19</p></td>
<td></td>
<td></td>
<td align="center" valign="middle"><p class="First">21</p></td>
</tr>
<tr><td colspan="5"><p class="First"><span class="Bold">Gastrointestinal System Disorders</span></p></td></tr>
<tr>
<td><p class="First">Â Â Â Â <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></p></td>
<td align="center" valign="middle"><p class="First">38</p></td>
<td></td>
<td valign="middle"></td>
<td align="center" valign="middle"><p class="First">40</p></td>
</tr>
<tr>
<td><p class="First">Â Â Â Â <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td align="center" valign="middle"><p class="First">29</p></td>
<td></td>
<td valign="middle"></td>
<td align="center" valign="middle"><p class="First">27</p></td>
</tr>
<tr>
<td><p class="First">Â Â Â Â <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td align="center" valign="middle"><p class="First">24</p></td>
<td></td>
<td valign="middle"></td>
<td align="center" valign="middle"><p class="First">25</p></td>
</tr>
<tr>
<td><p class="First">Â Â Â Â <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
<td align="center" valign="middle"><p class="First">23</p></td>
<td></td>
<td valign="middle"></td>
<td align="center" valign="middle"><p class="First">20</p></td>
</tr>
<tr>
<td><p class="First">Â Â Â Â <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></p></td>
<td align="center" valign="middle"><p class="First">23</p></td>
<td></td>
<td valign="middle"></td>
<td align="center" valign="middle"><p class="First">19</p></td>
</tr>
<tr>
<td><p class="First">Â Â Â Â <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">Abdominal pain upper</span></p></td>
<td align="center" valign="middle"><p class="First">14</p></td>
<td></td>
<td valign="middle"></td>
<td align="center" valign="middle"><p class="First">14</p></td>
</tr>
<tr>
<td><p class="First">Â Â Â Â <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span></p></td>
<td align="center" valign="middle"><p class="First">10</p></td>
<td></td>
<td valign="middle"></td>
<td align="center" valign="middle"><p class="First">13</p></td>
</tr>
<tr><td colspan="5"><p class="First"><span class="Bold">General and Administrative Site Disorders</span></p></td></tr>
<tr>
<td><p class="First">Â Â Â Â <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></p></td>
<td align="center" valign="middle"><p class="First">17</p></td>
<td></td>
<td></td>
<td align="center" valign="middle"><p class="First">18</p></td>
</tr>
<tr>
<td><p class="First">Â Â Â Â <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Edema lower limb</span></p></td>
<td align="center" valign="middle"><p class="First">16</p></td>
<td></td>
<td></td>
<td align="center" valign="middle"><p class="First">17</p></td>
</tr>
<tr>
<td><p class="First">Â Â Â Â <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span></p></td>
<td align="center" valign="middle"><p class="First">13</p></td>
<td></td>
<td></td>
<td align="center" valign="middle"><p class="First">19</p></td>
</tr>
<tr><td colspan="5"><p class="First"><span class="Bold">Investigations</span></p></td></tr>
<tr>
<td><p class="First">Â Â Â Â Increased blood creatinine</p></td>
<td align="center" valign="middle"><p class="First">15</p></td>
<td valign="middle"></td>
<td valign="middle"></td>
<td align="center" valign="middle"><p class="First">10</p></td>
</tr>
<tr><td colspan="5"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span></span></p></td></tr>
<tr>
<td><p class="First">Â Â Â Â <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infection</span></p></td>
<td align="center" valign="middle"><p class="First">29</p></td>
<td valign="middle"></td>
<td valign="middle"></td>
<td align="center" valign="middle"><p class="First">33</p></td>
</tr>
<tr>
<td><p class="First">Â Â Â Â <span class="product-label-link" type="condition" conceptid="440032" conceptname="Cytomegalovirus infection">CMV Infection</span></p></td>
<td align="center" valign="middle"><p class="First">20</p></td>
<td valign="middle"></td>
<td valign="middle"></td>
<td align="center" valign="middle"><p class="First">18</p></td>
</tr>
<tr><td colspan="5"><p class="First"><span class="Bold">Metabolism and Nutrition Disorders</span></p></td></tr>
<tr>
<td><p class="First">Â Â Â Â <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span></p></td>
<td align="center" valign="middle"><p class="First">11</p></td>
<td valign="middle"></td>
<td valign="middle"></td>
<td align="center" valign="middle"><p class="First">15</p></td>
</tr>
<tr>
<td><p class="First">Â Â Â Â <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">Hyperuricemia</span></p></td>
<td align="center" valign="middle"><p class="First">13</p></td>
<td valign="middle"></td>
<td valign="middle"></td>
<td align="center" valign="middle"><p class="First">13</p></td>
</tr>
<tr>
<td><p class="First">Â Â Â Â <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span></p></td>
<td align="center" valign="middle"><p class="First">12</p></td>
<td valign="middle"></td>
<td valign="middle"></td>
<td align="center" valign="middle"><p class="First">10</p></td>
</tr>
<tr>
<td><p class="First">Â Â Â Â <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span></p></td>
<td align="center" valign="middle"><p class="First">13</p></td>
<td valign="middle"></td>
<td valign="middle"></td>
<td align="center" valign="middle"><p class="First">9</p></td>
</tr>
<tr>
<td><p class="First">Â Â Â Â <span class="product-label-link" type="condition" conceptid="4177973" conceptname="Hypophosphatemia">Hypophosphatemia</span></p></td>
<td align="center" valign="middle"><p class="First">11</p></td>
<td valign="middle"></td>
<td valign="middle"></td>
<td align="center" valign="middle"><p class="First">9</p></td>
</tr>
<tr><td colspan="5"><p class="First"><span class="Bold">Musculoskeletal, Connective Tissue &amp;</span></p></td></tr>
<tr><td colspan="5"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="75909" conceptname="Disorder of bone">Bone Disorders</span></span></p></td></tr>
<tr>
<td><p class="First">Â Â Â Â <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span></p></td>
<td align="center" valign="middle"><p class="First">12</p></td>
<td valign="middle"></td>
<td valign="middle"></td>
<td align="center" valign="middle"><p class="First">6</p></td>
</tr>
<tr>
<td><p class="First">Â Â Â Â <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></p></td>
<td align="center" valign="middle"><p class="First">7</p></td>
<td valign="middle"></td>
<td valign="middle"></td>
<td align="center" valign="middle"><p class="First">11</p></td>
</tr>
<tr><td colspan="5"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorder</span></span></p></td></tr>
<tr>
<td><p class="First">Â Â Â Â <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></p></td>
<td align="center" valign="middle"><p class="First">24</p></td>
<td valign="middle"></td>
<td valign="middle"></td>
<td align="center" valign="middle"><p class="First">24</p></td>
</tr>
<tr>
<td><p class="First">Â Â Â Â <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span></p></td>
<td align="center" valign="middle"><p class="First">12</p></td>
<td valign="middle"></td>
<td valign="middle"></td>
<td align="center" valign="middle"><p class="First">14</p></td>
</tr>
<tr>
<td><p class="First">Â Â Â Â <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td align="center" valign="middle"><p class="First">13</p></td>
<td valign="middle"></td>
<td valign="middle"></td>
<td align="center" valign="middle"><p class="First">11</p></td>
</tr>
<tr><td colspan="5"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular Disorders</span></span></p></td></tr>
<tr class="Last">
<td class="Botrule"><p class="First">Â Â Â Â <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">18</p></td>
<td class="Botrule" valign="middle"></td>
<td class="Botrule" valign="middle"></td>
<td class="Botrule" align="center" valign="middle"><p class="First">18</p></td>
</tr>
</tbody>
</table>
<p>**The trial was not designed to support comparative claims for mycophenolic acid for the adverse reactions reported in this table.</p>
<p>Table 3 summarizes the incidence of <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span> in <span class="Italics">de novo</span> transplant patients.</p>
<p><span class="Bold">Table 3: Viral and <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">Fungal Infections</span> (%) Reported Over 0 to 12 Months</span></p>
<table cellpadding="0pt" cellspacing="0pt" width="100%">
<col width="30%">
<col width="3%">
<col width="33%">
<col width="33%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule"></td>
<td class="Toprule" align="center" colspan="3" valign="middle"><p class="First"><span class="Bold"><span class="Italics">de novo</span> Renal Trial</span></p></td>
</tr>
<tr>
<td class="Toprule" colspan="2"><p class="First"><span class="Bold">Â </span></p></td>
<td class="Toprule" align="center"><p class="First"><span class="Bold">Mycophenolic acid </span><br><span class="Bold">delayed-release tablets</span></p></td>
<td class="Toprule" align="center"><p class="First"><span class="Bold">mycophenolate mofetil (MMF)</span></p></td>
</tr>
<tr>
<td class="Botrule" colspan="2"></td>
<td class="Botrule" align="center" valign="middle"><p class="First"><span class="Bold">1.44 grams per day<br> (n=213)<br>(%)</span></p></td>
<td class="Botrule" align="center" valign="middle"><p class="First"><span class="Bold">2 grams per day<br>(n=210)<br>(%)</span></p></td>
</tr>
<tr>
<td colspan="2"><p class="First">Any CytomegalovirusÂ </p></td>
<td align="center" valign="middle"><p class="First">22</p></td>
<td align="center" valign="middle"><p class="First">21</p></td>
</tr>
<tr>
<td colspan="2"><p class="First">-Cytomegalovirus Disease </p></td>
<td align="center" valign="middle"><p class="First">5</p></td>
<td align="center" valign="middle"><p class="First">4</p></td>
</tr>
<tr>
<td colspan="2"><p class="First">Herpes Simplex</p></td>
<td align="center" valign="middle"><p class="First">8</p></td>
<td align="center" valign="middle"><p class="First">6</p></td>
</tr>
<tr>
<td colspan="2"><p class="First"><span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Herpes Zoster</span></p></td>
<td align="center" valign="middle"><p class="First">5</p></td>
<td align="center" valign="middle"><p class="First">4</p></td>
</tr>
<tr>
<td colspan="2"><p class="First">Any <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">Fungal Infection</span></p></td>
<td align="center" valign="middle"><p class="First">11</p></td>
<td align="center" valign="middle"><p class="First">12</p></td>
</tr>
<tr>
<td colspan="2"><p class="First">Â Â Â Â - <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> NOS</p></td>
<td align="center" valign="middle"><p class="First">6</p></td>
<td align="center" valign="middle"><p class="First">6</p></td>
</tr>
<tr class="Last">
<td class="Botrule" colspan="2"><p class="First">Â Â Â Â - <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> albicans</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">2</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">4</p></td>
</tr>
</tbody>
</table>
<p><span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span> developed in 2 <span class="Italics">de novo</span> patients (1%), (1 diagnosed 9 days after treatment initiation) and in 2 conversion patients (1%) receiving mycophenolic acid delayed-release tablets with other immunosuppressive agents in the 12-month controlled clinical trials.Â </p>
<p>Nonmelanoma skin carcinoma occurred in 1% <span class="Italics">de novo</span> and 12% conversion patients. Other types of malignancy occurred in 1% <span class="Italics">de novo</span> and 1% conversion patients [see <span class="Italics">Warnings and Precautions (<a href="#_ed06f621-44e8-4b42-883f-a48f07dae667">5.4</a>)</span>].Â </p>
<p>The adverse reactions reported in &lt;10% of <span class="Italics">de novo</span> or conversion patients treated with mycophenolic acid delayed-release tablets in combination with cyclosporine and corticosteroids are listed in Table 4.</p>
<p>Â <span class="Bold">Table 4: Adverse Reactions Reported in &lt;10% of Patients Treated with Mycophenolic Acid Delayed-Release Tablets in Combination with Cyclosporine* and Corticosteroids</span></p>
<table cellpadding="0pt" cellspacing="0pt" width="100%">
<col width="50%">
<col width="50%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule Toprule"><p class="First">Blood and Lymphatic Disorders</p></td>
<td class="Botrule Lrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="4119772" conceptname="Lymphocele">Lymphocele</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span></p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac Disorder</span></p></td>
<td class="Botrule Lrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span></p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye Disorder</span></p></td>
<td class="Botrule Lrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Vision blurred</span></p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></p></td>
<td class="Botrule Lrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">abdominal distension</span>, <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">gastroesophageal reflux disease</span>, gingival <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span></p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">General Disorders and Administration Site Conditions</p></td>
<td class="Botrule Lrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span></p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span></p></td>
<td class="Botrule Lrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">Nasopharyngitis</span>, herpes simplex, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory infection</span>, <span class="product-label-link" type="condition" conceptid="29735" conceptname="Candidiasis of mouth">oral candidiasis</span>, <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>, <span class="product-label-link" type="condition" conceptid="4153877" conceptname="Post-traumatic wound infection">wound infection</span>, implant <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span></p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">Investigations</p></td>
<td class="Botrule Lrule Toprule"><p class="First">Hemoglobin decrease, <span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">liver function tests abnormal</span></p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">Metabolism and Nutrition Disorders</p></td>
<td class="Botrule Lrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">Hypercholesterolemia</span>, <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>,</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">Connective Tissue Disorders</span></p></td>
<td class="Botrule Lrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span>, <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">pain in limb</span>, <span class="product-label-link" type="condition" conceptid="133299" conceptname="Swelling of limb">peripheral swelling</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramps</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span></p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></p></td>
<td class="Botrule Lrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> (excluding <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>)</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">Psychiatric Disorders</p></td>
<td class="Botrule Lrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span></p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">Renal and Urinary Disorders</p></td>
<td class="Botrule Lrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="444044" conceptname="Acute tubular necrosis">Renal tubular necrosis</span>, <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span></p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">Respiratory, Thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span></p></td>
<td class="Botrule Lrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="4263848" conceptname="Dyspnea on exertion">dyspnea exertional</span></p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">Skin and Subcutaneous Tissue Disorders</p></td>
<td class="Botrule Lrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></p></td>
</tr>
<tr class="Botrule Last">
<td class="Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular Disorders</span></p></td>
<td class="Lrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">Hypertension aggravated</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span></p></td>
</tr>
</tbody>
</table>
<p>*USP MODIFIED</p>
<p>The following additional adverse reactions have been associated with the exposure to mycophenolic acid (MPA) when administered as a sodium salt or as mofetil ester:</p>
<p><span class="Bold"><span class="Italics">Gastrointestinal</span>:</span> <span class="product-label-link" type="condition" conceptid="193242" conceptname="Perforation of intestine">Intestinal perforation</span>, <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcers</span>, <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcers</span> [see<span class="Italics"> Warnings and Precautions (<a href="#_dfa6ce1f-c95f-519b-a3c7-f7eb50619701">5.8</a>)</span>], <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span> (including <span class="product-label-link" type="condition" conceptid="4340797" conceptname="Cytomegaloviral colitis">CMV colitis</span>), <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>, and <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">ileus</span>.Â </p>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></span>: </span>Serious life-threatening <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> such as <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span> and infectious <span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">endocarditis</span>, <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>, and <span class="product-label-link" type="condition" conceptid="4008721" conceptname="Atypical mycobacterial infection">atypical mycobacterial infection</span> [see <span class="Italics">Warnings and Precautions (<a href="#_cc4ddf66-d669-608e-8287-64fed7c1ccfb">5.5</a>)</span>].</p>
<p><span class="Bold"><span class="Italics">Respiratory</span>:</span> Interstitial <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">lung disorders</span>, including fatal <span class="product-label-link" type="condition" conceptid="4197819" conceptname="Fibrosis of lung">pulmonary fibrosis</span>. Â </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_e279f1e1-4aea-cc59-5149-3087a3d8c1dc"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified during post-approval use of mycophenolic acid or other MPA derivatives. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<dl>
<dt>â€¢</dt>
<dd>Congenital malformations and an increased incidence of first trimester pregnancy loss have been reported following exposure to MMF during pregnancy [see <span class="Italics"><a href="#ID_f2a1f195-2afd-4f28-b2a3-0ec88a43595c">Boxed Warning</a>, Warnings and Precautions (<a href="#_37fc93c3-2aba-fe53-92ff-fdaeae47308a">5.1</a>)</span>].Â </dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> [see <span class="Italics">Warnings and Precautions (<a href="#_cc4ddf66-d669-608e-8287-64fed7c1ccfb">5.5</a>, <a href="#_25f42243-5613-f581-3853-781a818efbba">5.6</a>)</span>] <dl>
<dt>â€¢</dt>
<dd>Cases of <span class="product-label-link" type="condition" conceptid="433957" conceptname="Progressive multifocal leukoencephalopathy">progressive multifocal leukoencephalopathy</span> (PML), sometimes fatal.</dd>
<dt>â€¢</dt>
<dd>Polyomavirus associated <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">nephropathy</span> (PVAN), especially due to BK virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, associated with serious outcomes, including deteriorating renal function and renal graft loss.</dd>
<dt>â€¢</dt>
<dd>Viral reactivation in patients infected with HBV or HCV.</dd>
</dl>
</dd>
<dt>â€¢</dt>
<dd>Cases of pure <span class="product-label-link" type="condition" conceptid="4226622" conceptname="Decreased erythroid precursor production">red cell aplasia</span> (PRCA) have been reported in patients treated with MPA derivatives in combination with other immunosuppressive agents [see <span class="Italics">Warnings and Precautions (<a href="#_62addb2f-e8ac-b84b-a759-9a461e2cb7b5">5.7</a>)</span>].</dd>
</dl>
<p>The following additional adverse reactions have been identified during postapproval use of mycophenolic acid: <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="141663" conceptname="Osteomyelitis">osteomyelitis</span>, <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>, <span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">lymphopenia</span>, <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="196152" conceptname="Peritonitis">peritonitis</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, Kaposiâ€™s <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">sarcoma</span><span class="Italics">.Â </span></p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="_3540b164-ec67-460a-4914-d1adf9cc492e"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS </h1>
<div class="Section" data-sectionCode="42229-5">
<a name="_25006cf6-1a0f-5270-85c9-5f51338f89e7"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Antacids with Magnesium and Aluminum Hydroxides</h2>
<p class="First">Concomitant use of mycophenolic acid delayed-release tablets and antacids decreased plasma concentrations of mycophenolic acid (MPA). It is recommended that mycophenolic acid delayed-release tablets and antacids not be administered simultaneously [see <span class="Italics">Clinical Pharmacology (<a href="#_bb3d86be-45ce-556a-7931-10efd63f972f">12.3</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_e30e36fa-0828-bf14-eac9-c65a8d5caa03"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Azathioprine</h2>
<p class="First">Given that azathioprine and MMF inhibit purine metabolism, it is recommended that mycophenolic acid delayed-release tablets not be administered concomitantly with azathioprine or MMF.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_e1c43148-2bb3-d3ad-39be-55904c38d8fb"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Cholestyramine, Bile Acid Sequestrates, Oral Activated Charcoal and Other Drugs that Interfere with Enterohepatic Recirculation</h2>
<p class="First">Drugs that interrupt enterohepatic recirculation may decrease MPA plasma concentrations when coadministered with MMF. Therefore, do not administer mycophenolic acid delayed-release tablets with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, e.g., bile acid sequestrates or oral activated charcoal, because of the potential to reduce the efficacy of mycophenolic acid delayed-release tablets [see <span class="Italics">Clinical Pharmacology (<a href="#_bb3d86be-45ce-556a-7931-10efd63f972f">12.3</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_1d408f0b-ef8a-3835-996c-b330d3d76c1c"></a><a name="section-7.4"></a><p></p>
<h2>7.4Â  Sevelamer</h2>
<p class="First">Concomitant administration of sevelamer and MMF may decrease MPA plasma concentrations. Sevelamer and other calcium free phosphate binders should not be administered simultaneously with mycophenolic acid delayed-release tablets [see <span class="Italics">Clinical Pharmacology (<a href="#_bb3d86be-45ce-556a-7931-10efd63f972f">12.3</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_550160ee-23c3-c859-157a-29118cae59a3"></a><a name="section-7.5"></a><p></p>
<h2>7.5 Cyclosporine</h2>
<p class="First">Cyclosporine inhibits the enterohepatic recirculation of MPA, and therefore, MPA plasma concentrations may be decreased when mycophenolic acid delayed-release tablets are coadministered with cyclosporine. Clinicians should be aware that there is also a potential change of MPA plasma concentrations after switching from cyclosporine to other immunosuppressive drugs or from other immunosuppressive drugs to cyclosporine in patients concomitantly receiving mycophenolic acid delayed-release tablets [see <span class="Italics">Clinical Pharmacology (<a href="#_bb3d86be-45ce-556a-7931-10efd63f972f">12.3</a>)</span>].Â </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_3a22776d-4fc3-cee7-9508-924ac05af8af"></a><a name="section-7.6"></a><p></p>
<h2>7.6 Norfloxacin and Metronidazole</h2>
<p class="First">MPA plasma concentrations may be decreased when MMF is administrated with norfloxacin and metronidazole. Therefore, mycophenolic acid delayed-release tablets are not recommended to be given with the combination of norfloxacin and metronidazole. Although there will be no effect on MPA plasma concentrations when mycophenolic acid delayed-release tablets are concomitantly administered with norfloxacin or metronidazole when given separately [see <span class="Italics">Clinical Pharmacology (<a href="#_bb3d86be-45ce-556a-7931-10efd63f972f">12.3</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_cdc89a6c-1452-0190-1919-0b347922db7e"></a><a name="section-7.7"></a><p></p>
<h2>7.7 Rifampin</h2>
<p class="First">The concomitant administration of MMF and rifampin may decrease MPA plasma concentrations. Therefore, mycophenolic acid delayed-release tablets are not recommended to be given with rifampin concomitantly unless the benefit outweighs the risk [see <span class="Italics">Clinical Pharmacology (<a href="#_bb3d86be-45ce-556a-7931-10efd63f972f">12.3</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_805e298a-5962-9447-592c-6f80bf8d81c7"></a><a name="section-7.8"></a><p></p>
<h2>7.8 Hormonal Contraceptives</h2>
<p class="First">In a drug interaction study, mean levonorgestrel AUC was decreased by 15% when coadministered with MMF. Although mycophenolic acid delayed-release tablets may not have any influence on the ovulation-suppressing action of oral contraceptives, it is recommended to coadminister mycophenolic acid delayed- release tablets with hormonal contraceptives (e.g., birth control pill, transdermal patch, vaginal ring, injection, and implant) with caution, and additional barrier contraceptive methods must be used [see <span class="Italics">Warnings and Precautions (<a href="#_91d0387f-1afc-3a3a-3ace-f50b8d7f5af3">5.2</a>), Use in Specific Populations (<a href="#_a046b033-ca5e-1320-23ac-a01817599255">8.6</a>)</span>, and <span class="Italics">Clinical Pharmacology (<a href="#_bb3d86be-45ce-556a-7931-10efd63f972f">12.3</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_957caeb9-5f1b-7887-8cb1-2b72175e20aa"></a><a name="section-7.9"></a><p></p>
<h2>7.9 Acyclovir (Valacyclovir), Ganciclovir (Valganciclovir), and Other Drugs that Undergo Renal Tubular Secretion</h2>
<p class="First">The coadministration of MMF and acyclovir or ganciclovir may increase plasma concentrations of mycophenolic acid glucuronide (MPAG) and acyclovir/valacyclovir/ganciclovir/valganciclovir as their coexistence competes for tubular secretion. Both acyclovir/valacyclovir/ganciclovir/valganciclovir and MPAG concentrations will be also increased in the presence of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Acyclovir/valacyclovir/ganciclovir/valganciclovir may be taken with mycophenolic acid; however, during the period of treatment, physicians should monitor blood cell counts [see <span class="Italics">Clinical Pharmacology (<a href="#_bb3d86be-45ce-556a-7931-10efd63f972f">12.3</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_be1d90f4-5420-7d80-fc60-e5726e2f820e"></a><a name="section-7.10"></a><p></p>
<h2>7.10 Ciprofloxacin, Amoxicillin plus Clavulanic Acid and Other Drugs that Alter the Gastrointestinal Flora</h2>
<p class="First">Drugs that alter the gastrointestinal flora such as ciprofloxacin or amoxicillin plus clavulanic acid may interact with MMF by disrupting enterohepatic recirculation. Interference of MPAG hydrolysis may lead to less MPA available for absorption when mycophenolic acid delayed-release tablet is concomitantly administered with ciprofloxacin or amoxicillin plus clavulanic acid. The clinical relevance of this interaction is unclear; however, no dose adjustment of mycophenolic acid delayed-release tablet is needed when coadministered with these drugs [see <span class="Italics">Clinical Pharmacology (<a href="#_bb3d86be-45ce-556a-7931-10efd63f972f">12.3</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_7edaa5cd-b9c5-6e7f-054c-1844b59f6854"></a><a name="section-7.11"></a><p></p>
<h2>7.11Â Pantoprazole</h2>
<p class="First">Administration of a pantoprazole at a dose of 40 mg twice daily for 4 days to healthy volunteers did not alter the pharmacokinetics of a single dose of mycophenolic acid delayed-release tablets [see <span class="Italics">Clinical Pharmacology (<a href="#_bb3d86be-45ce-556a-7931-10efd63f972f">12.3</a>)</span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="_f81a478f-bf0a-7835-41d2-7b0069e56369"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="_4490778e-3820-1fbc-811d-87881d955316"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><span class="Bold">Pregnancy Category D<span class="Italics">Â </span>[See<span class="Italics"> Warnings and Precautions (<a href="#_37fc93c3-2aba-fe53-92ff-fdaeae47308a">5.1</a>)</span>]</span>Â </p>
<p>For those females using mycophenolic acid at any time during pregnancy and those becoming pregnant within 6 weeks of discontinuing therapy, the healthcare practitioner should report the pregnancy to the Mycophenolate Pregnancy Registry (1-800-617-8191). The healthcare practitioner should strongly encourage the patient to enroll in the pregnancy registry. The information provided to the registry will help the Health Care Community to better understand the effects of mycophenolate in pregnancy.</p>
<p><span class="Bold">Risk Summary</span></p>
<p>Following oral or intravenous (IV) administration, MMF is metabolized to mycophenolic acid (MPA), the active ingredient in mycophenolic acid delayed-release tablets and the active form of the drug. Use of MMF during pregnancy is associated with an increased risk of first trimester pregnancy loss and an increased risk of congenital malformations, especially external ear and other facial abnormalities including <span class="product-label-link" type="condition" conceptid="134144" conceptname="Cleft palate with cleft lip">cleft lip and palate</span>, and anomalies of the distal limbs, heart, esophagus, and kidney. In animal studies, congenital malformations and pregnancy loss occurred when pregnant rats and rabbits received mycophenolic acid at dose multiples similar to and less than clinical doses.</p>
<p>Risks and benefits of mycophenolic acid delayed-release tablets should be discussed with the patient. When appropriate, consider alternative immunosuppressants with less potential for embryofetal toxicity. In certain situations, the patient and her healthcare practitioner may decide that the maternal benefits outweigh the risks to the fetus. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.</p>
<p><span class="Bold">Data</span></p>
<p><span class="Bold">Human Data</span></p>
<p>In the National Transplantation Pregnancy Registry (NTPR), there were data on 33 MMF-exposed pregnancies in 24 transplant patients; there were 15 <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">spontaneous abortions</span> (45%) and 18 live-born infants. Four of these 18 infants had structural malformations (22%). In postmarketing data (collected from 1995 to 2007) on 77 women exposed to systemic MMF during pregnancy, 25 had <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">spontaneous abortions</span> and 14 had a malformed infant or fetus. Six of 14 malformed offspring had ear abnormalities. Because these postmarketing data are reported voluntarily, it is not always possible to reliably estimate the frequency of particular adverse outcomes. These malformations are similar to findings in animal reproductive toxicology studies. For comparison, the background rate for congenital anomalies in the United States is about 3%, and NTPR data show a rate of 4% to 5% among babies born to organ transplant patients using other immunosuppressive drugs. There are no relevant qualitative or quantitative differences in the teratogenic potential of mycophenolate sodium and MMF.</p>
<p><span class="Bold">Animal Data</span>Â </p>
<p>In a teratology study performed with mycophenolate sodium in rats, at a dose as low as 1 mg per kg, malformations in the offspring were observed, including <span class="product-label-link" type="condition" conceptid="434143" conceptname="Anophthalmos">anophthalmia</span>, <span class="product-label-link" type="condition" conceptid="4309376" conceptname="Exencephaly">exencephaly</span>, and <span class="product-label-link" type="condition" conceptid="4245842" conceptname="Umbilical hernia">umbilical hernia</span>. The systemic exposure at this dose represents 0.05 times the clinical exposure at the dose of 1440 mg per day mycophenolic acid delayed-release tablets. In teratology studies in rabbits, fetal resorptions and malformations occurred at doses equal to or greater than 80 mg per kg per day, in the absence of maternal toxicity (which corresponds to about 1.1 times the recommended clinical dose, based on body surface area).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_69a7ec3a-0a4a-afff-b845-11e7a6e7e93e"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether MPA is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from mycophenolic acid delayed-release tablets, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_576fe3a9-1603-9da3-2ce3-2bc46cf81300"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">The safety and effectiveness of mycophenolic acid delayed-release tablets have been established in pediatric kidney transplant patients 5 to 16 years of age who were initiated on mycophenolic acid delayed-release tablets at least 6 months post-transplant. Use of mycophenolic acid delayed-release tablets in this age group is supported by evidence from adequate and well-controlled studies of mycophenolic acid delayed-release tablets in a similar population of adult kidney transplant patients with additional pharmacokinetic data in pediatric kidney transplant patients [see <span class="Italics">Dosage and Administration (<a href="#_6174dd6a-75fc-9084-fe51-d1997a955536">2.2</a>, <a href="#_63836cf5-69e1-327a-5aa1-2efa96de1c9e">2.3</a>)</span>, <span class="Italics">Clinical Pharmacology (<a href="#_bb3d86be-45ce-556a-7931-10efd63f972f">12.3</a>)</span>]. Pediatric doses for patients with BSA &lt;1.19 m<span class="Sup">2</span> cannot be accurately administered using currently available formulations of mycophenolic acid delayed-release tablets.Â </p>
<p>The safety and effectiveness of mycophenolic acid delayed-release tablets in <span class="Italics">de novo</span> pediatric kidney transplant patients and in pediatric kidney transplant patients below the age of 5 years have not been established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_b78f1e76-6cb9-e064-ddc3-92eff3a455df"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Clinical studies of mycophenolic acid delayed-release tablets did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Of the 372 patients treated with mycophenolic acid delayed-release tablets in the clinical trials, 6% (N=21) were 65 years of age and older and 0.3% (N=1) were 75 years of age and older. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_a046b033-ca5e-1320-23ac-a01817599255"></a><a name="section-8.5"></a><p></p>
<h2>8.6 Females of Reproductive Potential Pregnancy Exposure Prevention and Planning  </h2>
<p class="First">Females of reproductive potential must be made aware of the increased risk of first trimester pregnancy loss and congenital malformations and must be counseled regarding pregnancy prevention and planning.</p>
<p>Females of reproductive potential include girls who have entered puberty and all women who have a uterus and have not passed through <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span>. <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">Menopause</span> is the permanent end of menstruation and fertility. <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">Menopause</span> should be clinically confirmed by a patientâ€™s healthcare practitioner. Some commonly used diagnostic criteria include 1) 12 months of spontaneous <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span> (not <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span> induced by a medical condition or medical therapy), or 2) postsurgical from a bilateral oophorectomy.</p>
<p><span class="Bold">Pregnancy Testing</span></p>
<p>To prevent unplanned exposure during pregnancy, females of reproductive potential should have a serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL immediately before starting mycophenolic acid delayed-release tablets. Another pregnancy test with the same sensitivity should be done 8 to 10 days later. Repeat pregnancy tests should be performed during routine follow-up visits. Results of all pregnancy tests should be discussed with the patient.</p>
<p>In the event of a <span class="product-label-link" type="condition" conceptid="4094910" conceptname="Pregnancy test positive">positive pregnancy test</span>, females should be counseled with regard to whether the maternal benefits of mycophenolate treatment may outweigh the risks to the fetus in certain situations.</p>
<p><span class="Bold">Contraception</span></p>
<p>Females of reproductive potential taking mycophenolic acid delayed-release tablets must receive contraceptive counseling and use acceptable contraception (see Table 5 for Acceptable Contraception Methods). Patients must use acceptable birth control during entire mycophenolic acid delayed-release tablets therapy, and for 6 weeks after stopping mycophenolic acid delayed-release tablets, unless the patient chooses abstinence (she chooses to avoid heterosexual intercourse completely).Â </p>
<p>Patients should be aware that mycophenolic acid delayed-release tablets reduce blood levels of the hormones in the oral contraceptive pill and could theoretically reduce its effectiveness [see <span class="Italics">Patient Counseling Information (<a href="#_893ec398-61fa-d7af-2aa3-6df65254f505">17</a>)</span>, <span class="Italics">Drug Interactions (<a href="#_805e298a-5962-9447-592c-6f80bf8d81c7">7.8</a>)</span>].</p>
<p><span class="Bold">Table 5: Acceptable Contraception Methods for Females of Reproductive Potential</span></p>
<p><span class="Bold"><span class="Italics">Pick from the following birth control options:</span></span></p>
<table width="100%">
<col width="27%">
<col width="16%">
<col width="12%">
<col width="16%">
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" colspan="4"><p class="First"><span class="Bold">Option 1</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Methods to Use AloneÂ </span></p></td>
<td class="Botrule Lrule Rrule Toprule" colspan="3"><p class="First">Â Intrauterine devices (IUDs)<br>Â Tubal sterilization<br>Â Patientâ€™s partner had a vasectomy</p></td>
</tr>
<tr><td class="Botrule" colspan="4"><p class="First">OR</p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Option 2</span>Â </p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">Hormone Methods</span><br>choose 1</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Â </p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">Barrier Methods</span><br>choose 1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Choose One Hormone Method</span><br><span class="Italics">AND</span>Â <span class="Bold">One Barrier Method</span>Â Â  Â  Â  Â  Â  Â  </p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">Estrogen and Progesterone</span><br>Oral Contraceptive Pill<br>Transdermal patch<br>Vaginal ring<br><span class="Bold">Progesterone-only</span><br>Injection</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Italics">AND</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Diaphragm with spermicide<br>Cervical cap with spermicide<br>Contraceptive sponge<br>Male condom<br>Female condomÂ  Â  Â  Â  Â </p></td>
</tr>
<tr><td class="Botrule" colspan="4"><p class="First">OR</p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Option 3</span>Â </p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">Barrier Methods</span><br>choose 1</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Italics">Â </span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">Barrier Methods</span><br>choose 1</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">Choose One Barrier Method</span>Â <span class="Bold">from each column <span class="Italics">(must choose two methods)</span></span>Â Â  Â  </p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Diaphragm with spermicide<br>Cervical cap with spermicide<br>Contraceptive spongeÂ  Â  </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Italics">AND</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Male condom<br>Female condomÂ  Â  Â  </p></td>
</tr>
</tbody>
</table>
<p><span class="Bold">Pregnancy PlanningÂ </span></p>
<p>For patients who are considering pregnancy, consider alternative immunosuppressants with less potential for embryofetal toxicity. Risks and benefits of mycophenolic acid delayed-release tablets should be discussed with the patient.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="_7baa7d19-25d7-7d4d-8b6a-ef54275901b7"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE </h1>
<p class="First"><span class="Bold">Signs and Symptoms</span>Â </p>
<p>There have been anecdotal reports of deliberate or accidental <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> with mycophenolic acid delayed-release tablets, whereas not all patients experienced related adverse reactions.Â </p>
<p>In those <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> cases in which adverse reactions were reported, the reactions <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> within the known safety profile of the class. Accordingly an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of mycophenolic acid delayed-release tablets could possibly result in over suppression of the immune system and may increase the susceptibility to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> including <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span>, fatal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> and <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>. If <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood dyscrasias</span> occur (e.g., <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> with absolute neutrophil count &lt;1.5 x 10<span class="Sup">3</span>/mcL or <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>), it may be appropriate to interrupt or discontinue mycophenolic acid delayed-release tablets.Â </p>
<p>Possible signs and symptoms of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">acute overdose</span> could include the following: hematological abnormalities such as <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> and <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, and <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span> such as <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>.</p>
<p><span class="Bold">Treatment and ManagementÂ </span></p>
<p>General supportive measures and symptomatic treatment should be followed in all cases of overdosage. Although dialysis may be used to remove the inactive metabolite mycophenolic acid glucuronide (MPAG), it would not be expected to remove clinically significant amounts of the active moiety, mycophenolic acid, due to the 98% plasma protein binding of mycophenolic acid. By interfering with enterohepatic circulation of mycophenolic acid, activated charcoal or bile sequestrates, such as cholestyramine, may reduce the systemic mycophenolic acid exposure.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="_9E5571A4-82FA-9BB9-3094-40416392DB70"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Mycophenolic acid delayed-release tablets are an enteric formulation of mycophenolate sodium that delivers the active moiety mycophenolic acid (MPA). Mycophenolic acid is an immunosuppressive agent. As the sodium salt, MPA is chemically designated as (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methylhex-4-enoic acid sodium salt. </p>
<p>Its molecular formula is C<span class="Sub">17</span>H<span class="Sub">19</span>O<span class="Sub">6</span> Na. The molecular weight is 342.32 and the structural formula is </p>
<div class="Figure">
<a name="id1738"></a><img alt="mycophenolic-structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=26b31126-4262-4a15-8a16-234c86763176&amp;name=mycophenolicfigure.jpg">
</div>
<p>Mycophenolic acid, as the sodium salt, is a white to off-white, crystalline powder and is highly soluble in aqueous media at physiological pH and practically insoluble in 0.1N hydrochloric acid.</p>
<p>Mycophenolic acid is available for oral use as delayed-release tablets containing 180 mg or 360 mg of mycophenolic acid. Inactive ingredients include methylcellulose, sodium lauryl sulfate, stearic acid, colloidal silicon dioxide, hypromellose and polyethylene glycol. The enteric coating of the tablet consists of triethyl citrate, talc, titanium dioxide, yellow ferric oxide (180 mg and 360 mg), indigotine al lake (180 mg), methacrylic acid and ethyl acrylate copolymer dispersion, and red ferric oxide (360 mg).</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="_9c153092-b1bd-bf5e-19b5-7f52987dad3d"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="_2bfb4735-ff70-3cde-9ab8-bd2118b1ced2"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Mycophenolic acid (MPA), an immunosuppressant, is an uncompetitive and reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH), and therefore inhibits the <span class="Italics">de novo</span> pathway of guanosine nucleotide synthesis without incorporation to DNA. T- and B-<span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> are critically dependent for their proliferation on <span class="Italics">de novo</span> synthesis of purines, whereas other cell types can utilize salvage pathways. MPA has cytostatic effects on <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>.Â </p>
<p>Mycophenolate sodium has been shown to prevent the occurrence of acute rejection in rat models of kidney and heart allotransplantation. Mycophenolate sodium also decreases antibody production in mice.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_bb3d86be-45ce-556a-7931-10efd63f972f"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">Mycophenolic acid delayed-release tablets exhibit linear and dose-proportional pharmacokinetics over the dose-range (360 to 2160 mg) evaluated. The absolute bioavailability of mycophenolic acid delayed-release tablets in stable renal transplant patients on cyclosporine was 72%. MPA is highly protein bound (&gt;98% bound to albumin). The predominant metabolite of MPA is the phenolic glucuronide (MPAG) which is pharmacologically inactive. A minor metabolite AcMPAG which is an acyl glucuronide of MPAG is also formed and has pharmacological activity comparable to MPA. MPAG undergoes renal elimination. A fraction of MPAG also undergoes biliary excretion, followed by deconjugation by gut flora and subsequent reabsorption as MPA. The mean elimination half-lives of MPA and MPAG ranged between 8 and 16 hours, and 13 and 17 hours, respectively.</p>
<p><span class="Bold"><span class="Italics">AbsorptionÂ </span></span></p>
<p><span class="Italics">In vitro</span> studies demonstrated that the enteric-coated mycophenolic acid tablet does not release MPA under acidic conditions (pH &lt;5) as in the stomach but is highly soluble in neutral pH conditions as in the intestine. Following mycophenolic acid oral administration without food in several pharmacokinetic studies conducted in renal transplant patients, consistent with its enteric-coated formulation, the median delay (T<span class="Sub">lag)</span> in the rise of MPA concentration ranged between 0.25 and 1.25 hours and the median time to maximum concentration (T<span class="Sub">max</span>) of MPA ranged between 1.5 and 2.75 hours. In comparison, following the administration of MMF, the median T<span class="Sub">max</span> ranged between 0.5 and 1.0 hours. In stable renal transplant patients on cyclosporine, USP MODIFIED based <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span>, gastrointestinal absorption and absolute bioavailability of MPA following the administration of mycophenolic acid delayed-release tablet was 93% and 72%, respectively. Mycophenolic acid delayed-release tablets pharmacokinetics is dose proportional over the dose range of 360 to 2160 mg.Â </p>
<p><span class="Bold"><span class="Italics">DistributionÂ </span></span></p>
<p>The mean (Â± SD) volume of distribution at steady state and elimination phase for MPA is 54 (Â± 25) L and 112 (Â± 48) L, respectively. MPA is highly protein bound to albumin, &gt;98%. The protein binding of mycophenolic acid glucuronide (MPAG) is 82%. The free MPA concentration may increase under conditions of decreased protein binding (<span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">uremia</span>, <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>, and <span class="product-label-link" type="condition" conceptid="4001047" conceptname="Hypoalbuminemia">hypoalbuminemia</span>).Â </p>
<p><span class="Bold"><span class="Italics">Metabolism</span></span></p>
<p>MPA is metabolized principally by glucuronyl transferase to glucuronidated metabolites. The phenolic glucuronide of MPA, mycophenolic acid glucuronide (MPAG), is the predominant metabolite of MPA and does not manifest pharmacological activity. The acyl glucuronide is a minor metabolite and has comparable pharmacological activity to MPA. In stable renal transplant patients on cyclosporine, USP MODIFIED based <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span>, approximately 28% of the oral mycophenolic acid delayed-release tablets dose was converted to MPAG by presystemic metabolism. The AUC ratio of MPA:MPAG:acyl glucuronide is approximately 1:24:0.28 at steady state. The mean clearance of MPA was 140 (Â± 30) mL/min.Â </p>
<p><span class="Bold"><span class="Italics">EliminationÂ </span></span></p>
<p>The majority of MPA dose administered is eliminated in the urine primarily as MPAG (&gt;60%) and approximately 3% as unchanged MPA following mycophenolic acid administration to stable renal transplant patients. The mean renal clearance of MPAG was 15.5 (Â± 5.9) mL/min. MPAG is also secreted in the bile and available for deconjugation by gut flora. MPA resulting from the deconjugation may then be reabsorbed and produce a second peak of MPA approximately 6 to 8 hours after mycophenolic acid dosing. The mean elimination half-life of MPA and MPAG ranged between 8 and 16 hours, and 13 and 17 hours, respectively.Â </p>
<p><span class="Bold"><span class="Italics">Food EffectÂ </span></span></p>
<p>Compared to the fasting state, administration of mycophenolic acid delayed-release tablets 720 mg with a high-fat meal (55 g fat, 1000 calories) had no effect on the systemic exposure (AUC) of MPA. However, there was a 33% decrease in the maximal concentration (Cmax), a 3.5-hour delay in the Tlag (range, -6 to 18 hours), and 5.0-hour delay in the Tmax (range, -9 to 20 hours) of MPA. To avoid the variability in MPA absorption between doses, mycophenolic acid delayed-release tablets should be taken on an empty stomach [see<span class="Italics"> Dosage and Administration (<a href="#_63836cf5-69e1-327a-5aa1-2efa96de1c9e">2.3</a>)</span>].Â </p>
<p><span class="Bold">Pharmacokinetics in Renal Transplant PatientsÂ </span></p>
<p>The mean pharmacokinetic parameters for MPA following the administration of mycophenolic acid in renal transplant patients on cyclosporine, USP MODIFIED based <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> are shown in Table 6. Single-dose mycophenolic acid pharmacokinetics predicts multiple-dose pharmacokinetics. However, in the early post-transplant period, mean MPA AUC and C<span class="Sub">max</span> were approximately one-half of those measured 6 months post-transplant.Â </p>
<p>After near equimolar dosing of mycophenolic acid 720 mg twice daily and MMF 1000 mg twice daily (739 mg as MPA) in both the single- and multiple-dose cross-over trials, mean systemic MPA exposure (AUC) was similar.</p>
<p><span class="Bold">Table 6: Mean Â± SD Pharmacokinetic Parameters for MPA Following the Oral Administration of Mycophenolic Acid Delayed-Release Tablets to Renal Transplant Patients on Cyclosporine, USP MODIFIED Based <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">Immunosuppression</span></span></p>
<table width="100%">
<col width="12%">
<col width="14%">
<col width="6%">
<col width="6%">
<col width="6%">
<col width="8%">
<col width="7%">
<col width="6%">
<col width="10%">
<col width="6%">
<col width="6%">
<col width="13%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Toprule" valign="bottom"><p class="First"><span class="Bold">Patient</span></p></td>
<td class="Botrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">Mycophenolic Acid </span><br><span class="Bold">Delayed-Release TabletsÂ </span><br><span class="Bold">Dosing</span></p></td>
<td class="Botrule Toprule"></td>
<td class="Botrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">N</span></p></td>
<td class="Botrule Toprule" valign="bottom"></td>
<td class="Botrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold">Dose</span><br><span class="Bold"> (mg)</span></p></td>
<td class="Botrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold">T<span class="Sub">max</span>* (hr)</span></p></td>
<td class="Botrule Toprule"></td>
<td class="Botrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold">C<span class="Sub">max</span>Â </span><br><span class="Bold">(mcg/mL)</span></p></td>
<td class="Botrule Toprule" valign="bottom"></td>
<td class="Botrule Toprule" valign="bottom"></td>
<td class="Botrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold">AUC</span><span class="Sub">0Â -12hr</span><span class="Bold">Â </span><br><span class="Bold">(mcg*hr/mL)</span></p></td>
</tr>
<tr>
<td class="Toprule"><p class="First">Adult</p></td>
<td class="Toprule"><p class="First">Single</p></td>
<td class="Toprule"></td>
<td class="Toprule" align="center" valign="middle"><p class="First">24</p></td>
<td class="Toprule"></td>
<td class="Toprule" align="center" valign="middle"><p class="First">720</p></td>
<td class="Toprule" align="center" valign="middle"><p class="First">2 (0.8 â€“ 8)</p></td>
<td class="Toprule"></td>
<td class="Toprule" align="center" valign="middle"><p class="First">26.1 Â± 12.0</p></td>
<td class="Toprule"></td>
<td class="Toprule"></td>
<td class="Toprule" align="center" valign="middle"><p class="First">66.5 Â± 22.6**</p></td>
</tr>
<tr>
<td><p class="First">Pediatric***</p></td>
<td><p class="First">Single</p></td>
<td></td>
<td align="center" valign="middle"><p class="First">10</p></td>
<td></td>
<td align="center" valign="middle"><p class="First">450/m<span class="Sup">2</span></p></td>
<td align="center" valign="middle"><p class="First">2.5 (1.5 â€“ 24)</p></td>
<td></td>
<td align="center" valign="middle"><p class="First">36.3 Â± 20.9</p></td>
<td></td>
<td></td>
<td align="center" valign="middle"><p class="First">74.3 Â± 22.5**</p></td>
</tr>
<tr>
<td><p class="First">Adult</p></td>
<td><p class="First">Multiple x6 days, twice daily</p></td>
<td></td>
<td align="center" valign="middle"><p class="First">10</p></td>
<td></td>
<td align="center" valign="middle"><p class="First">720</p></td>
<td align="center" valign="middle"><p class="First">2 (1.5 â€“ 3.0)</p></td>
<td></td>
<td align="center" valign="middle"><p class="First">37.0 Â± 13.3</p></td>
<td></td>
<td></td>
<td align="center" valign="middle"><p class="First">67.9 Â± 20.3</p></td>
</tr>
<tr>
<td><p class="First">Adult</p></td>
<td><p class="First">Multiple x28 days, twice daily</p></td>
<td></td>
<td align="center" valign="middle"><p class="First">36</p></td>
<td></td>
<td align="center" valign="middle"><p class="First">720</p></td>
<td align="center" valign="middle"><p class="First">2.5 (1.5 â€“ 8)</p></td>
<td></td>
<td align="center" valign="middle"><p class="First">31.2 Â± 18.1</p></td>
<td></td>
<td></td>
<td align="center" valign="middle"><p class="First">71.2 Â± 26.3</p></td>
</tr>
<tr>
<td><p class="First">Adult</p></td>
<td><p class="First">Chronic, multiple dose, twice daily</p></td>
<td></td>
<td valign="middle"></td>
<td></td>
<td valign="middle"></td>
<td valign="middle"></td>
<td></td>
<td valign="middle"></td>
<td></td>
<td></td>
<td valign="middle"></td>
</tr>
<tr>
<td><p class="First">Â </p></td>
<td><p class="First">2 weeks post-transplant</p></td>
<td></td>
<td align="center" valign="middle"><p class="First">12</p></td>
<td></td>
<td align="center" valign="middle"><p class="First">720</p></td>
<td align="center" valign="middle"><p class="First">1.8 (1.0 â€“ 5.3)</p></td>
<td></td>
<td align="center" valign="middle"><p class="First">15.0 Â± 10.7</p></td>
<td></td>
<td></td>
<td align="center" valign="middle"><p class="First">28.6 Â± 11.5</p></td>
</tr>
<tr>
<td><p class="First">Â </p></td>
<td><p class="First">3 months post-transplant</p></td>
<td></td>
<td align="center" valign="middle"><p class="First">12</p></td>
<td></td>
<td align="center" valign="middle"><p class="First">720</p></td>
<td align="center" valign="middle"><p class="First">2 (0.5 â€“ 2.5)</p></td>
<td></td>
<td align="center" valign="middle"><p class="First">26.2 Â± 12.7</p></td>
<td></td>
<td></td>
<td align="center" valign="middle"><p class="First">52.3 Â± 17.4</p></td>
</tr>
<tr>
<td><p class="First">Â </p></td>
<td><p class="First">6 months post-transplant</p></td>
<td></td>
<td align="center" valign="middle"><p class="First">12</p></td>
<td></td>
<td align="center" valign="middle"><p class="First">720</p></td>
<td align="center" valign="middle"><p class="First">2 (0 â€“ 3)</p></td>
<td></td>
<td align="center" valign="middle"><p class="First">24.1 Â± 9.6</p></td>
<td></td>
<td></td>
<td align="center" valign="middle"><p class="First">57.2 Â± 15.3</p></td>
</tr>
<tr>
<td><p class="First">Adult</p></td>
<td><p class="First">Chronic, multiple dose, twice daily</p></td>
<td></td>
<td align="center" valign="middle"><p class="First">18</p></td>
<td></td>
<td align="center" valign="middle"><p class="First">720</p></td>
<td align="center" valign="middle"><p class="First">1.5 (0 â€“ 6)</p></td>
<td></td>
<td align="center" valign="middle"><p class="First">18.9 Â± 7.9</p></td>
<td></td>
<td></td>
<td align="center" valign="middle"><p class="First">57.4 Â± 15.0</p></td>
</tr>
<tr class="Last"><td class="Botrule" colspan="12"></td></tr>
</tbody>
</table>
<p>*median (range), ** AUC<span class="Sub">inf</span>, *** age range of 5-16 years</p>
<p><span class="Bold">Specific Populations</span></p>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span></span>:</span> No specific pharmacokinetic studies in individuals with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> were conducted with mycophenolic acid delayed-release tablets. However, based on studies of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> with MMF, MPA exposure is not expected to be appreciably increased over the range of normal to severely <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> following mycophenolic acid delayed-release tablets administration.Â </p>
<p>In contrast, MPAG exposure would be increased markedly with decreased renal function; MPAG exposure being approximately 8-fold higher in the setting of <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span>. Although dialysis may be used to remove the inactive metabolite MPAG, it would not be expected to remove clinically significant amounts of the active moiety MPA. This is in large part due to the high plasma protein binding of MPA.</p>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span>:</span></span> No specific pharmacokinetic studies in individuals with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> were conducted with mycophenolic acid delayed-release tablets. In a single dose (MMF 1000 mg) trial of 18 volunteers with <span class="product-label-link" type="condition" conceptid="196463" conceptname="Alcoholic cirrhosis">alcoholic cirrhosis</span> and 6 healthy volunteers, hepatic MPA glucuronidation processes appeared to be relatively unaffected by hepatic parenchymal disease when the pharmacokinetic parameters of healthy volunteers and <span class="product-label-link" type="condition" conceptid="196463" conceptname="Alcoholic cirrhosis">alcoholic cirrhosis</span> patients within this trial were compared. However, it should be noted that for unexplained reasons, the healthy volunteers in this trial had about a 50% lower AUC compared to healthy volunteers in other studies, thus making comparison between volunteers with <span class="product-label-link" type="condition" conceptid="196463" conceptname="Alcoholic cirrhosis">alcoholic cirrhosis</span> and healthy volunteers difficult. Effects of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span> on this process probably depend on the particular disease. <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic disease</span>, such as <span class="product-label-link" type="condition" conceptid="4135822" conceptname="Primary biliary cirrhosis">primary biliary cirrhosis</span>, with other etiologies may show a different effect.</p>
<p><span class="Bold"><span class="Italics">Pediatrics:</span></span> Limited data are available on the use of mycophenolic acid delayed-release tablets at a dose of 450 mg/m<span class="Sup">2</span> body surface area in children. The mean MPA pharmacokinetic parameters for stable pediatric renal transplant patients, 5 to 16 years, on cyclosporine, USP MODIFIED are shown in Table 6. At the same dose administered based on body surface area, the respective mean C<span class="Sub">max</span> and AUC of MPA determined in children were higher by 33% and 18% than those determined for adults. The clinical impact of the increase in MPA exposure is not known [see <span class="Italics">Dosage and Administration (<a href="#_6174dd6a-75fc-9084-fe51-d1997a955536">2.2</a>, </span><a href="#_63836cf5-69e1-327a-5aa1-2efa96de1c9e">2.3</a><span class="Italics">)</span>].</p>
<p><span class="Bold"><span class="Italics">Gender:</span></span> There are no significant gender differences in mycophenolic acid delayed-release tablets pharmacokinetics.Â </p>
<p><span class="Bold"><span class="Italics">Elderly:</span></span> Pharmacokinetics in the elderly have not been formally studied.Â </p>
<p><span class="Bold"><span class="Italics">Ethnicity:</span></span> Following a single dose administration of 720 mg of mycophenolic acid delayed-release tablets to 18 Japanese and 18 Caucasian healthy subjects, the exposure (AUC<span class="Sub">inf</span>) for MPA and MPAG were 15% and 22% lower in Japanese subjects compared to Caucasians. The peak concentrations (C<span class="Sub">max</span>) for MPAG were similar between the two populations, however, Japanese subjects had 9.6% higher C<span class="Sub">max</span> for MPA. These results do not suggest any clinically relevant differences.</p>
<p><span class="Bold">Drug Interactions:</span></p>
<p><span class="Italics">Antacids with Magnesium and Aluminum Hydroxides:</span></p>
<p>Absorption of a single dose of mycophenolic acid delayed-release tablets was decreased when administered to 12 stable kidney transplant patients also taking magnesium-aluminum-containing antacids (30 mL): the mean C<span class="Sub">max</span> and AUC<span class="Sub">(0 to t)</span> values for MPA were 25% and 37% lower, respectively, than when mycophenolic acid delayed-release tablets were administered alone under fasting conditions [see<span class="Italics"> Drug Interactions (<a href="#_25006cf6-1a0f-5270-85c9-5f51338f89e7">7.1</a>)</span><span class="Bold">]</span>.Â </p>
<p><span class="Italics">Pantoprazole: </span></p>
<p>In a trial conducted in 12 healthy volunteers, the pharmacokinetics of MPA were observed to be similar when a single dose of 720 mg of mycophenolic acid delayed-release tablets was administered alone and following concomitant administration of mycophenolic acid delayed-release tablets and pantoprazole, which was administered at a dose of 40 mg twice daily for 4 days [see <span class="Italics">Drug Interactions (<a href="#_7edaa5cd-b9c5-6e7f-054c-1844b59f6854">7.11</a>)</span>].</p>
<p><span class="Bold"><span class="Italics">The following drug interaction studies were conducted following the administration of MMF:</span></span></p>
<p><span class="Italics">Cholestyramine</span>Â </p>
<p>Following single-dose oral administration of 1.5 grams MMF to 12 healthy volunteers pretreated with 4 grams three times daily of cholestyramine for 4 days, MPA AUC decreased approximately 40%. This decrease is consistent with interruption of enterohepatic recirculation which may be due to binding of recirculating MPAG with cholestyramine in the intestine [see <span class="Italics">Drug Interactions (7.3)</span>].Â </p>
<p><span class="Italics">Sevelamer</span></p>
<p>Concomitant administration of sevelamer and MMF in stable adult and pediatric kidney transplant patients decreased the mean MPA C<span class="Sub">max</span> and AUC<span class="Sub">(0 to 12h)</span> by 36% and 26% respectively [see <span class="Italics">Drug Interactions (<a href="#_1d408f0b-ef8a-3835-996c-b330d3d76c1c">7.4</a>)</span>].Â </p>
<p><span class="Italics">Cyclosporine</span></p>
<p>Cyclosporine (Sandimmune<span class="Sup">Â®</span>) pharmacokinetics (at doses of 275 to 415 mg/day) were unaffected by single and multiple doses of 1.5 grams twice daily of MMF in 10 stable kidney transplant patients. The mean (Â±SD) AUC<span class="Sub">(0 to 12h)</span> and C<span class="Sub">max</span> of cyclosporine after 14 days of multiple doses of MMF were 3290 (Â±822) ngâ€¢h/mL and 753 (Â±161) ng/mL, respectively, compared to 3245 (Â±1088) ngâ€¢h/mL and 700 (Â±246) ng/mL, respectively, 1 week before administration of MMF.</p>
<p>A total of 73 <span class="Italics">de novo</span> kidney allograft recipients on MMF therapy received either low dose cyclosporine withdrawal by 6 months post-transplant (50 to 100 ng/mL for up to 3 months post-transplant followed by complete withdrawal at month 6 post-transplant) or standard dose cyclosporine (150 to 300 ng/mL from baseline through to month 4 post-transplant and 100 to 200 ng/mL thereafter). At month 12 post-transplant, the mean MPA (AUC<span class="Sub">(0 to 12h)</span>) in the cyclosporine withdrawal group was approximately 40% higher, than that of the standard dose cyclosporine group.Â </p>
<p>Cyclosporine inhibits multidrug-resistance-associated protein 2 (MRP-2) transporter in the biliary tract, thereby preventing the excretion of MPAG into the bile that would lead to enterohepatic recirculation of MPA [see <span class="Italics">Drug Interactions (<a href="#_550160ee-23c3-c859-157a-29118cae59a3">7.5</a>)</span>].Â </p>
<p><span class="Italics">Norfloxacin</span> and <span class="Italics">Metronidazole</span>Â </p>
<p>Following single-dose administration of MMF (1 g) to 11 healthy volunteers on day 4 of a 5 day course of a combination of norfloxacin and metronidazole, the mean MPA AUC<span class="Sub">(0 to 48h)</span> was reduced by 33% compared to the administration of MMF alone (p&lt;0.05). There was no significant effect on mean MPA AUC<span class="Sub">(0 to 48h)</span> when MMF was concomitantly administered with norfloxacin or metronidazole separately. The mean (Â±SD) MPA AUC<span class="Sub">(0 to 48h) </span>after coadministration of MMF with norfloxacin or metronidazole separately was 48.3 (Â±24) mcgâ€¢h/mL and 42.7 (Â±23) mcgâ€¢h/mL, respectively, compared with 56.2 (Â±24) mcgâ€¢h/mL after administration of MMF alone [see <span class="Italics">Drug Interactions (<a href="#_3a22776d-4fc3-cee7-9508-924ac05af8af">7.6</a>)</span>].Â </p>
<p><span class="Italics">Rifampin</span>Â </p>
<p>In a single heart-lung transplant patient on MMF therapy (1 gram twice daily), a 67% decrease in MPA exposure (AUC<span class="Sub">(0 to12h)</span>) was observed with concomitant administration of MMF and 600 mg rifampin daily.Â </p>
<p>In 8 kidney transplant patients on stable MMF therapy (1 gram twice daily), administration of 300 mg rifampin twice daily resulted in a 17.5% decrease in MPA AUC<span class="Sub">(0 to 12h) </span>due to inhibition of enterohepatic recirculation of MPAG by rifampin. Rifampin coadministration also resulted in a 22.4% increase in MPAG AUC<span class="Sub">(0 to 12h)</span> [see <span class="Italics">Drug Interactions (<a href="#_cdc89a6c-1452-0190-1919-0b347922db7e">7.7</a>)</span>].Â </p>
<p><span class="Italics">Oral Contraceptives</span>Â </p>
<p>In a drug-drug interaction trial, mean AUCs were similar for ethinyl estradiol and norethindrone, when coadministered with MMF as compared to administration of the oral contraceptives alone [see <span class="Italics">Drug Interactions (<a href="#_805e298a-5962-9447-592c-6f80bf8d81c7">7.8</a>)</span>].Â </p>
<p><span class="Italics">Acyclovir</span></p>
<p>Coadministration of MMF (1 gram) and acyclovir (800 mg) to 12 healthy volunteers resulted in no significant change in MPA AUC and C<span class="Sub">max</span>. However, MPAG and acyclovir plasma mean AUC<span class="Sub">(0 to 24h)</span> were increased 10% and 18%, respectively. Because MPAG plasma concentrations are increased in the presence of kidney impairment, as are acyclovir concentrations, the potential exists for mycophenolate and acyclovir or its prodrug (e.g., valacyclovir) to compete for tubular secretion, further increasing the concentrations of both drugs [see <span class="Italics">Drug Interactions (<a href="#_957caeb9-5f1b-7887-8cb1-2b72175e20aa">7.9</a>)</span>].</p>
<p><span class="Italics">Ganciclovir</span></p>
<p>Following single-dose administration to 12 stable kidney transplant patients, no <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span> was observed between MMF (1.5 grams) and intravenous ganciclovir (5 mg per kg). Mean (Â±SD) ganciclovir AUC and C<span class="Sub">max</span> (n=10) were 54.3 (Â±19.0) mcgâ€¢h/mL and 11.5 (Â±1.8) mcg/mL, respectively, after coadministration of the two drugs, compared to 51.0 (Â±17.0) mcgâ€¢h/mL and 10.6 (Â±2.0) mcg/mL, respectively, after administration of intravenous ganciclovir alone. The mean (Â±SD) AUC and C<span class="Sub">max</span> of MPA (n=12) after coadministration were 80.9 (Â±21.6) mcgâ€¢h/mL and 27.8 (Â±13.9) mcg/mL, respectively, compared to values of 80.3 (Â±16.4) mcgâ€¢h/mL and 30.9 (Â±11.2) mcg/mL, respectively, after administration of MMF alone.Â </p>
<p>Because MPAG plasma concentrations are increased in the presence of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, as are ganciclovir concentrations, the two drugs will compete for tubular secretion and thus further increases in concentrations of both drugs may occur. In patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> in which MMF and ganciclovir or its prodrug (e.g., valganciclovir) are coadministered, patients should be monitored carefully [see <span class="Italics">Drug Interactions (<a href="#_957caeb9-5f1b-7887-8cb1-2b72175e20aa">7.9</a>)</span>].</p>
<p><span class="Italics">Ciprofloxacin and Amoxicillin plus Clavulanic Acid</span>Â </p>
<p>A total of 64 MMF treated kidney transplant recipients received either oral ciprofloxacin 500 mg twice daily or amoxicillin plus clavulanic acid 375 mg three times daily for 7 or at least 14 days. Approximately 50% reductions in median trough MPA concentrations (predose) from baseline (MMF alone) were observed in 3 days following commencement of oral ciprofloxacin or amoxicillin plus clavulanic acid. These reductions in trough MPA concentrations tended to diminish within 14 days of antibiotic therapy and ceased within 3 days after discontinuation of antibiotics. The postulated mechanism for this interaction is an antibiotic-induced reduction in glucuronidase-possessing enteric organisms leading to a decrease in enterohepatic recirculation of MPA. The change in trough level may not accurately represent changes in overall MPA exposure; therefore, clinical relevance of these observations is unclear [see <span class="Italics">Drug Interactions (<a href="#_be1d90f4-5420-7d80-fc60-e5726e2f820e">7.10</a>)</span>].Â </p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="_62f2b0d8-168e-17d9-0a0d-2d7bb5fbf05d"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="_a2d334ae-547c-c44e-f2e7-8e1b8cec94c8"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">In a 104-week oral carcinogenicity study in rats, mycophenolate sodium was not tumorigenic at daily doses up to 9 mg per kg, the highest dose tested. This dose resulted in approximately 0.6 to 1.2 times the systemic exposure (based on plasma AUC) observed in renal transplant patients at the recommended dose of 1440 mg per day. Similar results were observed in a parallel study in rats performed with MMF. In a 104-week oral carcinogenicity study in mice, MMF was not tumorigenic at a daily dose level as high as 180 mg per kg (which corresponds to 0.6 times the recommended mycophenolate sodium therapeutic dose, based on body surface area).</p>
<p>The genotoxic potential of mycophenolate sodium was determined in five assays. Mycophenolate sodium was genotoxic in the mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>/thymidine kinase assay, the micronucleus test in V79 Chinese hamster cells, and the <span class="Italics">in vivo</span> mouse micronucleus assay. Mycophenolate sodium was not genotoxic in the bacterial mutation assay (<span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> typhimurium</span> TA 1535, 97a, 98, 100, and 102) or the chromosomal aberration assay in human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>.</p>
<p>Mycophenolate mofetil generated similar genotoxic activity. The genotoxic activity of mycophenolic acid (MPA) is probably due to the depletion of the nucleotide pool required for DNA synthesis as a result of the pharmacodynamic mode of action of MPA (inhibition of nucleotide synthesis).</p>
<p>Mycophenolate sodium had no effect on male rat fertility at daily oral doses as high as 18 mg per kg and exhibited no testicular or spermatogenic effects at daily oral doses of 20 mg per kg for 13 weeks (approximately 2 times the systemic exposure of MPA at the recommended therapeutic dose). No effects on female fertility were seen up to a daily dose of 20 mg per kg (approximately 3 times the systemic exposure of MPA at the recommended therapeutic dose).</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="_f0f22198-9f91-b9b1-8980-10cfb36c80e8"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES </h1>
<div class="Section" data-sectionCode="42229-5">
<a name="_343ef33f-bea7-144a-029e-cbd622997815"></a><a name="section-13.1"></a><p></p>
<h2>14. 1 Prophylaxis of Organ Rejection in Patients Receiving Allogeneic Renal Transplants</h2>
<p class="First">The safety and efficacy of mycophenolic acid delayed-release tablets in combination with cyclosporine, USP MODIFIED and corticosteroids for the prevention of organ rejection was assessed in two multicenter, randomized, double-blind active-controlled trials in <span class="Italics">de novo</span> and conversion renal transplant patients compared to MMF.Â </p>
<p>The <span class="Italics">de novo</span> trial was conducted in 423 renal transplant patients (ages 18 to 75 years) in Austria, Canada, Germany, Hungary, Italy, Norway, Spain, UK, and USA. Eighty-four percent of randomized patients received kidneys from deceased donors. Patients were excluded if they had second or multi-organ (e.g., kidney and pancreas) transplants, or previous transplant with any other organs; kidneys from non-heart beating donors; panel reactive antibodies (PRA) of &gt;50% at last assessment prior to transplantation, and presence of severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, active <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer disease</span>, or uncontrolled <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus. Patients were administered either mycophenolic acid delayed-release tablets 1.44 grams per day or MMF 2 grams per day within 48 hours post-transplant for 12 months in combination with cyclosporine, USP MODIFIED and corticosteroids. Forty-one percent of patients received antibody therapy as induction treatment. Treatment failure was defined as the first occurrence of biopsy proven acute rejection, graft loss, <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or lost to follow-up at 6 months.</p>
<p>The incidence of treatment failure was similar in mycophenolic acid delayed-release tablets - and MMF-treated patients at 6 and 12 months (Table 7). The cumulative incidence of graft loss, <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> and lost to follow-up at 12 months is also shown in Table 7.</p>
<p><span class="Bold">Table 7: Treatment Failure in <span class="Italics">de novo</span> Renal Transplant Patients (Percent of Patients) at 6 and 12 Months of Treatment when Administered in Combination with Cyclosporine* and Corticosteroids</span></p>
<table cellpadding="0pt" cellspacing="0pt" width="100%">
<col width="20%">
<col width="20%">
<col width="20%">
<col width="20%">
<col width="20%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Toprule"><p class="First"><span class="Bold">Â </span></p></td>
<td class="Botrule Toprule" align="center"><p class="First"><span class="Bold">Mycophenolic acid</span><br><span class="Bold">delayed-release tablets</span><br><span class="Bold"> 1.44 grams per day</span><br><span class="Bold">(n=213)</span></p></td>
<td class="Botrule Toprule"></td>
<td class="Botrule Toprule"></td>
<td class="Botrule Toprule" align="center"><p class="First"><span class="Bold">mycophenolate</span><br><span class="Bold"> mofetil (MMF)</span><br><span class="Bold">2 grams per day</span><br><span class="Bold">(n=210)</span></p></td>
</tr>
<tr>
<td class="Toprule"><p class="First"><span class="Bold">6 Months</span><br>Â Â Â Â Â Â Treatment failure#</p></td>
<td class="Toprule" align="center"><p class="First"><span class="Bold">n (%)</span><br>55 (25.8)</p></td>
<td class="Toprule"></td>
<td class="Toprule"></td>
<td class="Toprule" align="center"><p class="First"><span class="Bold">n (%)</span><br>55 (26.2)</p></td>
</tr>
<tr>
<td><p class="First">Â Â Â Â Â Â Biopsy-proven acute rejection</p></td>
<td align="center"><p class="First">46 (21.6)</p></td>
<td></td>
<td></td>
<td align="center"><p class="First">48 (22.9)</p></td>
</tr>
<tr>
<td><p class="First">Â Â Â Â Â Â Graft loss</p></td>
<td align="center"><p class="First">7 (3.3)</p></td>
<td></td>
<td></td>
<td align="center"><p class="First">9 (4.3)</p></td>
</tr>
<tr>
<td><p class="First">Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span></p></td>
<td align="center"><p class="First">1 (0.5)</p></td>
<td></td>
<td></td>
<td align="center"><p class="First">2 (1.0)</p></td>
</tr>
<tr>
<td class="Botrule"><p class="First">Â Â Â Â Â Â Lost to follow-up**</p></td>
<td class="Botrule" align="center"><p class="First">3 (1.4)</p></td>
<td class="Botrule"></td>
<td class="Botrule"></td>
<td class="Botrule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">12 Months</span></p></td>
<td align="center"><p class="First"><span class="Bold">n (%)</span></p></td>
<td></td>
<td></td>
<td align="center"><p class="First"><span class="Bold">n (%)</span></p></td>
</tr>
<tr>
<td><p class="First">Â Â Â Â Â Â Graft loss or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span><br> or lost to follow-up***</p></td>
<td align="center"><p class="First">20 (9.4)</p></td>
<td></td>
<td></td>
<td align="center"><p class="First">18 (8.6)</p></td>
</tr>
<tr>
<td><p class="First">Â Â Â Â Â Â Treatment failure##</p></td>
<td align="center"><p class="First">61 (28.6)</p></td>
<td></td>
<td></td>
<td align="center"><p class="First">59 (28.1)</p></td>
</tr>
<tr>
<td><p class="First">Â Â Â Â Â Â Biopsy-proven acute rejection</p></td>
<td align="center"><p class="First">48 (22.5)</p></td>
<td></td>
<td></td>
<td align="center"><p class="First">51 (24.3)</p></td>
</tr>
<tr>
<td><p class="First">Â Â Â Â Â Â Graft loss</p></td>
<td align="center"><p class="First">9 (4.2)</p></td>
<td></td>
<td></td>
<td align="center"><p class="First">9 (4.3)</p></td>
</tr>
<tr>
<td><p class="First">Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span></p></td>
<td align="center"><p class="First">2 (0.9)</p></td>
<td></td>
<td></td>
<td align="center"><p class="First">5 (2.4)</p></td>
</tr>
<tr class="Last">
<td><p class="First">Â Â Â Â Â Â Lost to follow-up**</p></td>
<td align="center"><p class="First">5 (2.3)</p></td>
<td></td>
<td></td>
<td align="center"><p class="First">0</p></td>
</tr>
</tbody>
</table>
<p>*USP MODIFIED<br>**Lost to follow-up indicates patients who were lost to follow-up without prior biopsy-proven acute rejection, graft loss or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span><br>***Lost to follow-up indicates patients who were lost to follow-up without prior graft loss or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> (9 mycophenolic acid delayed-release tablets patients and 4 MMF patients)<br>#95% confidence interval of the difference in treatment failure at 6 months (mycophenolic acid delayed-release tablets â€“ MMF) is (-8.7%, 8.0%).<br>##95% confidence interval of the difference in treatment failure at 12 months (mycophenolic acid delayed-release tablets â€“ MMF) is (-8.0%, 9.1%).</p>
<p>Â The conversion trial was conducted in 322 renal transplant patients (ages 18â€“75 years), who were at least 6 months post-transplant and had undergone primary or secondary, deceased donor, living related, or unrelated donor kidney transplant, stable graft function (serum creatinine &lt;2.3 mg/mL), no change in immunosuppressive regimen due to graft malfunction, and no known clinically significant physical and/or laboratory changes for at least 2 months prior to enrollment. Patients were excluded if they had 3 or more kidney transplants, multiorgan transplants (e.g., kidney and pancreas), previous organ transplants, evidence of <span class="product-label-link" type="condition" conceptid="4248020" conceptname="Graft rejection">graft rejection</span> or who had been treated for acute rejection within 2 months prior to screening, clinically significant <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> requiring continued therapy, presence of severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, active <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer disease</span>, or uncontrolled <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus.Â </p>
<p>Patients received 2 grams per day MMF in combination with cyclosporine USP MODIFIED, with or without corticosteroids for at least two weeks prior to entry in the trial. Patients were randomized to mycophenolic acid delayed-release tablets 1.44 grams per day or MMF 2 grams per day for 12 months. The trial was conducted in Austria, Belgium, Canada, Germany, Italy, Spain, and USA. Treatment failure was defined as the first occurrence of biopsy-proven acute rejection, graft loss, <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, or lost to follow-up at 6 and 12 months.Â </p>
<p>The incidences of treatment failure at 6 and 12 months were similar between mycophenolic acid delayed- release tablets - and MMF-treated patients (Table 8). The cumulative incidence of graft loss, <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> and lost to follow-up at 12 months is also shown in Table 8.</p>
<p><span class="Bold">Table 8: Treatment Failure in Conversion Transplant Patients (Percent of Patients) at 6 and 12 Months of Treatment when Administered in Combination with Cyclosporine* and with or without Corticosteroids </span></p>
<table cellpadding="0pt" cellspacing="0pt" width="100%">
<col width="20%">
<col width="20%">
<col width="20%">
<col width="20%">
<col width="20%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Toprule"><p class="First"><span class="Bold">Â </span></p></td>
<td class="Botrule Toprule" align="center"><p class="First"><span class="Bold">Mycophenolic acid</span><br><span class="Bold">delayed-release tablets</span><br><span class="Bold">1.44 grams per day</span><br><span class="Bold">(n=159)</span></p></td>
<td class="Botrule Toprule"></td>
<td class="Botrule Toprule"></td>
<td class="Botrule Toprule" align="center"><p class="First"><span class="Bold">mycophenolate</span><br><span class="Bold"> mofetil (MMF)</span><br><span class="Bold">2 grams per day</span><br><span class="Bold">(n=163)</span></p></td>
</tr>
<tr>
<td class="Toprule"><p class="First"><span class="Bold">6 Months</span><br>Â Â Â Â Â Â Treatment failure#</p></td>
<td class="Toprule" align="center"><p class="First"><span class="Bold">n (%)</span><br>7 (4.4)</p></td>
<td class="Toprule"></td>
<td class="Toprule"></td>
<td class="Toprule" align="center"><p class="First"><span class="Bold">n (%)</span><br>11 (6.7)</p></td>
</tr>
<tr>
<td><p class="First">Â Â Â Â Â Â Biopsy-proven acute rejection</p></td>
<td align="center"><p class="First">2 (1.3)</p></td>
<td></td>
<td></td>
<td align="center"><p class="First">2 (1.2)</p></td>
</tr>
<tr>
<td><p class="First">Â Â Â Â Â Â Graft loss</p></td>
<td align="center"><p class="First">0</p></td>
<td></td>
<td></td>
<td align="center"><p class="First">1 (0.6)</p></td>
</tr>
<tr>
<td><p class="First">Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span></p></td>
<td align="center"><p class="First">0</p></td>
<td></td>
<td></td>
<td align="center"><p class="First">1 (0.6)</p></td>
</tr>
<tr>
<td class="Botrule"><p class="First">Â Â Â Â Â Â Lost to follow-up**</p></td>
<td class="Botrule" align="center"><p class="First">5 (3.1)</p></td>
<td class="Botrule"></td>
<td class="Botrule"></td>
<td class="Botrule" align="center"><p class="First">7 (4.3)</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">12 Months</span></p></td>
<td align="center"><p class="First"><span class="Bold">n (%)</span></p></td>
<td></td>
<td></td>
<td align="center"><p class="First"><span class="Bold">n (%)</span></p></td>
</tr>
<tr>
<td><p class="First">Â Â Â Â Â Â Graft loss or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or lost to follow-up***</p></td>
<td align="center"><p class="First">10 (6.3)</p></td>
<td></td>
<td></td>
<td align="center"><p class="First">17 (10.4)</p></td>
</tr>
<tr>
<td><p class="First">Â Â Â Â Â Â Treatment failure##</p></td>
<td align="center"><p class="First">12 (7.5)</p></td>
<td></td>
<td></td>
<td align="center"><p class="First">20 (12.3)</p></td>
</tr>
<tr>
<td><p class="First">Â Â Â Â Â Â Biopsy-proven acute rejection</p></td>
<td align="center"><p class="First">2 (1.3)</p></td>
<td></td>
<td></td>
<td align="center"><p class="First">5 (3.1)</p></td>
</tr>
<tr>
<td><p class="First">Â Â Â Â Â Â Graft loss</p></td>
<td align="center"><p class="First">0</p></td>
<td></td>
<td></td>
<td align="center"><p class="First">1 (0.6)</p></td>
</tr>
<tr>
<td><p class="First">Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span></p></td>
<td align="center"><p class="First">2 (1.3)</p></td>
<td></td>
<td></td>
<td align="center"><p class="First">4 (2.5)</p></td>
</tr>
<tr class="Last">
<td><p class="First">Â Â Â Â Â Â Lost to follow-up**</p></td>
<td align="center"><p class="First">8 (5.0)</p></td>
<td></td>
<td></td>
<td align="center"><p class="First">10 (6.1)</p></td>
</tr>
</tbody>
</table>
<p>*USP MODIFIED<br>**Lost to follow-up indicates patients who were lost to follow-up without prior biopsy-proven acute rejection, graft loss, or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span><br>***Lost to follow-up indicates patients who were lost to follow-up without prior graft loss or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> (8 mycophenolic acid delayed- release tablets patients and 12 MMF patients)<br>#95% confidence interval of the difference in treatment failure at 6 months (mycophenolic acid delayed-release tablets â€“ MMF) is (-7.3%, 2.7%).<br>##95% confidence interval of the difference in treatment failure at 12 months (mycophenolic acid delayed-release tablets â€“ MMF) is (-11.2%, 1.8%).</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="_69BF8344-12F6-3995-F897-5EE480998993"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Mycophenolic Acid Delayed-Release Tablets are supplied as:</p>
<p><span class="Bold">180 mg tablet:</span> Light green, round, slightly biconvex beveled edge enteric coated tablet.Â  Engraved â€œMYCâ€? over â€œ180â€? on one side, â€œAPOâ€? on the other side, containing 180 mg mycophenolic acid (MPA) as mycophenolate sodium.</p>
<p>Unit dose packages of 30 (3 x 10) NDC 68084-907-21</p>
<p><span class="Bold">360 mg tablet:</span> Light pink, oval, biconvex enteric coated tablet. Engraved â€œAPOâ€? on one side, â€œMYC 360â€? on the other side, containing 360 mg mycophenolic acid (MPA) as mycophenolate sodium.</p>
<p>Unit dose packages of 30 (5 x 6) NDC 68084-918-25</p>
<p><span class="Bold">Storage</span></p>
<p>Store at 25Â°C (77Â°F); excursions permitted to 15 to 30Â°C (59 to 86Â°F) [see USP Controlled Room Temperature]. Protect from moisture. </p>
<p><span class="Bold">Handling</span></p>
<p>Keep out of reach and sight of children. Mycophenolic acid delayed-release tablets should not be crushed or cut in order to maintain the integrity of the enteric coating [see <span class="Italics">Dosage and Administration (<a href="#_63836cf5-69e1-327a-5aa1-2efa96de1c9e">2.3</a>)</span>].</p>
<p>Teratogenic effects have been observed with mycophenolate sodium [see <span class="Italics">Warnings and Precautions (<a href="#_37fc93c3-2aba-fe53-92ff-fdaeae47308a">5.1</a>)</span>]. If for any reason, the mycophenolic acid delayed-release tablets must be crushed, avoid inhalation of the powder, or direct contact of the powder, with skin or mucous membranes.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="_893ec398-61fa-d7af-2aa3-6df65254f505"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First"><span class="Bold">See FDA-approved patient labeling (<a href="#_1F11955F-DB8E-C7EB-585D-28E34D989BBB">Medication Guide</a>) </span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="_267e9c74-9da5-7916-530f-db857b8c3e0a"></a><a name="section-15.1"></a><p></p>
<p class="First"><span class="Bold">Embryofetal Toxicity</span></p>
<dl>
<dt>â€¢</dt>
<dd>Inform pregnant women and females of reproductive potential that use of mycophenolic acid delayed-release tablets in pregnancy is associated with an increased risk of first trimester pregnancy loss and an increased risk of congenital malformations. [see <span class="Italics">Use in Specific Populations (<a href="#_4490778e-3820-1fbc-811d-87881d955316">8.1</a>)</span>].</dd>
<dt>â€¢</dt>
<dd>In the event of a <span class="product-label-link" type="condition" conceptid="4094910" conceptname="Pregnancy test positive">positive pregnancy test</span>, discuss the risks and benefits of mycophenolic acid delayed-release tablets with the patient. Encourage her to enroll in the pregnancy registry. (1-800-617-8191). [see <span class="Italics">Use in Specific Populations (<a href="#_4490778e-3820-1fbc-811d-87881d955316">8.1</a>)</span>].</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_371e2343-80c7-5ba6-d311-95192aca4871"></a><a name="section-15.2"></a><p></p>
<p class="First"><span class="Bold">Pregnancy Exposure Prevention and Planning</span></p>
<dl>
<dt>â€¢</dt>
<dd>Discuss pregnancy testing, pregnancy prevention and planning with females of reproductive potential [see <span class="Italics">Females of Reproductive Potential (<a href="#_a046b033-ca5e-1320-23ac-a01817599255">8.6</a>)</span>].</dd>
<dt>â€¢</dt>
<dd>Inform females of reproductive potential must use acceptable birth control during entire mycophenolic acid delayed-release tablets therapy and for 6 weeks after stopping mycophenolic acid delayed-release tablets, unless the patient chooses to avoid heterosexual sexual intercourse completely (abstinence) [see <span class="Italics">Warnings and Precautions (<a href="#_91d0387f-1afc-3a3a-3ace-f50b8d7f5af3">5.2</a>) </span>and <span class="Italics">Females of Reproductive Potential (<a href="#_a046b033-ca5e-1320-23ac-a01817599255">8.6</a>)</span>].</dd>
<dt>â€¢</dt>
<dd>For patients who are considering pregnancy, discuss appropriate alternative immunosuppressants with less potential for embryofetal toxicity. Risks and benefits of mycophenolic acid delayed-release tablets should be discussed with the patient [see <span class="Italics">Females of Reproductive Potential (<a href="#_a046b033-ca5e-1320-23ac-a01817599255">8.6</a>)</span>].</dd>
</dl>
<p><span class="Bold">Nursing Mothers</span>Â </p>
<p>Advise patients that they should not breastfeed during mycophenolic acid delayed-release tablets therapy [see <span class="Italics">Nursing Mothers (<a href="#_69a7ec3a-0a4a-afff-b845-11e7a6e7e93e">8.3</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_a57cb43f-aa78-35fa-d8fd-7fc3909728fa"></a><a name="section-15.3"></a><p></p>
<p class="First"><span class="Bold">Development of <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span> and Other Malignancies</span></p>
<dl>
<dt>â€¢</dt>
<dd>Inform patients they are at increased risk of developing <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphomas</span> and other malignancies, particularly of the skin, due to <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span>.</dd>
<dt>â€¢</dt>
<dd>Advise patients to limit exposure to sunlight and ultraviolet (UV) light by wearing protective clothing and use a sunscreen with a high protection factor.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_4b46b9cb-7ade-35dc-17a4-e4dc0df173ae"></a><a name="section-15.4"></a><p></p>
<p class="First"><span class="Bold">Increased Risk of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></span></p>
<p>Inform patients they are at increased risk of developing a variety of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, including <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span>, due to <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> and to contact their physician if they develop any symptoms of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> [see <span class="Italics">Warnings and Precautions (<a href="#_cc4ddf66-d669-608e-8287-64fed7c1ccfb">5.5</a>, <a href="#_25f42243-5613-f581-3853-781a818efbba">5.6</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_b0df16d2-69ce-7910-3fc5-7a8c2585017d"></a><a name="section-15.5"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">Blood Dyscrasias</span></span></p>
<p>Inform patients they are at increased risk for developing <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood dyscrasias</span> (e.g., <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> or <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>) and to immediately contact their healthcare provider if they experience any evidence of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, unexpected <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, or any other manifestation of bone marrow suppression [see <span class="Italics">Warnings and Precautions (<a href="#_62addb2f-e8ac-b84b-a759-9a461e2cb7b5">5.7</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_1892ba06-b42b-c4b0-bf44-468ec6202937"></a><a name="section-15.6"></a><p></p>
<p class="First"><span class="Bold">Gastrointestinal Tract Complications</span></p>
<p>Inform patients that mycophenolic acid delayed-release tablets can cause gastrointestinal tract complications including <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, <span class="product-label-link" type="condition" conceptid="193242" conceptname="Perforation of intestine">intestinal perforations</span>, and gastric or <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcers</span>. Advise the patient to contact their healthcare provider if they have symptoms of <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span> or sudden onset or persistent <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> [see <span class="Italics">Warnings and Precautions (<a href="#_dfa6ce1f-c95f-519b-a3c7-f7eb50619701">5.8</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_2e07f328-9d13-7e48-f759-99b01ec963e3"></a><a name="section-15.7"></a><p></p>
<p class="First"><span class="Bold">Immunizations</span></p>
<p>Inform patients that mycophenolic acid delayed-release tablets can interfere with the usual response to immunizations and that they should avoid live vaccines [see <span class="Italics">Warnings and Precautions (<a href="#_5600c5d2-d10b-f30d-65b2-72be4c9c5bb3">5.9</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_41d69fef-f585-b2c8-ed60-172e03823b1e"></a><a name="section-15.8"></a><p></p>
<p class="First"><span class="Bold">Administration Instructions</span></p>
<p>Advise patients to swallow mycophenolic acid delayed-release tablets whole, and not crush, chew, or cut the tablets. Inform patients to take mycophenolic acid delayed-release tablets on an empty stomach, 1 hour before or 2 hours after food intake.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_0a18c748-4be8-8162-80ab-821035754b33"></a><a name="section-15.9"></a><p></p>
<p class="First"><span class="Bold">Drug Interactions</span></p>
<p>Patients should be advised to report to their doctor the use of any other medications while taking mycophenolic acid delayed-release tablets. The simultaneous administration of any of the following drugs with mycophenolic acid delayed-release tablets may result in clinically significant adverse reactions:Â </p>
<p>Antacids with magnesium and aluminum hydroxides </p>
<p>Azathioprine</p>
<p>CholestyramineÂ </p>
<p>Hormonal Contraceptives (e.g., birth control pill, transdermal patch, vaginal ring, injection, and implant)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_08e0c865-b4a7-8a47-dd68-e367fc8de26b"></a><a name="section-15.10"></a><p></p>
<p class="First"><span class="Bold">PACKAGING INFORMATION</span></p>
<p>American Health Packaging unit dose <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> (see <a href="#_69BF8344-12F6-3995-F897-5EE480998993">How Supplied</a> section) contain drug product from Apotex Corp. as follows:<br>(180 mg/ 30 UD) NDC 68084-907-21 packaged from NDC 60505-2965<br>(360 mg/ 30 UD) NDC 68084-918-25 packaged from NDC 60505-2966</p>
<p>Packaged and Distributed by:<br><span class="Bold">American Health Packaging <br></span>Columbus, OH 43217</p>
<p>8290721/1114</p>
</div>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="_1F11955F-DB8E-C7EB-585D-28E34D989BBB"></a><a name="section-16"></a><p></p>
<h1>MEDICATION GUIDE</h1>
<p class="First"><span class="Bold">Mycophenolic Acid Delayed-Release Tablets </span></p>
<p><span class="Bold">(my-co-fen-o-lic acid)</span></p>
<p>Read the Medication Guide that comes with mycophenolic acid delayed-release tablets before you start taking it and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking with your healthcare provider about your medical condition or treatment. If you have any questions about mycophenolic acid delayed-release tablets, ask your doctor.</p>
<p><span class="Bold">What is the most important information I should know about mycophenolic acid delayed-release tablets?</span></p>
<p><span class="Bold">Mycophenolic acid delayed-release tablets can cause serious side effects including:</span></p>
<dl>
<dt>â€¢</dt>
<dd>
<span class="Bold">Increased risk of loss of pregnancy (<span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">miscarriage</span>) and higher risk of <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span>. </span>Females who take mycophenolic acid delayed-release tablets during pregnancy, have a higher risk of <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">miscarriage</span> during the first 3 months (first trimester), and a higher risk that their baby will be born with <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span>.<br><br>If you are a female who can become pregnant:<br>
</dd>
<dt>â€¢</dt>
<dd>your doctor must talk with you about acceptable birth control methods (contraceptive counseling) while taking mycophenolic acid delayed-release tablets.</dd>
<dt>â€¢</dt>
<dd>you should have a pregnancy test immediately before starting mycophenolic acid delayed-release tablets and another pregnancy test 8 to 10 days later. Pregnancy tests should be repeated during routine follow-up visits with your doctor. Talk to your doctor about the results of all of your pregnancy tests.</dd>
<dt>â€¢</dt>
<dd>you must use acceptable birth control during your entire mycophenolic acid delayed-release tablets therapy and for 6 weeks after stopping mycophenolic acid delayed-release tablets, unless at anytime you choose to avoid sexual intercourse (abstinence) with a man completely. Mycophenolic acid delayed-release tablets decrease blood levels of the hormones in birth control pills that you take by mouth. Birth control pills may not work as well while you take mycophenolic acid delayed-release tablets and you could become pregnant. If you decide to take birth control pills while using mycophenolic acid delayed-release tablets, you must also use another form of birth control. Talk to your doctor about other birth control methods that can be used while taking mycophenolic acid delayed-release tablets.</dd>
</dl>
<p>If you plan to become pregnant, talk with your doctor. Your doctor will decide if other medicines to prevent rejection may be right for you.</p>
<dl>
<dt>â€¢</dt>
<dd>If you become pregnant while taking mycophenolic acid delayed-release tablets, <span class="Underline">do not </span>stop taking mycophenolic acid delayed-release tablets. Call your doctor right away. In certain situations, you and your doctor may decide that taking mycophenolic acid delayed-release tablets is more important to your health than the possible risks to your unborn baby. </dd>
<dt>â€¢</dt>
<dd>You and your doctor should report your pregnancy to <dl>
<dt>â–ª</dt>
<dd>Mycophenolate Pregnancy Registry (1-800-617-8191) </dd>
</dl>
</dd>
</dl>
<p>The purpose of this registry is to gather information about the health of your baby.</p>
<dl>
<dt>â€¢</dt>
<dd>
<span class="Bold">Increased risk of getting serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. </span>Mycophenolic acid delayed-release tablets weaken the body's immune system and affect your ability to fight <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. Serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can happen with mycophenolic acid delayed-release tablets and can lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. These serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can include: <dl>
<dt>â€¢</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">Viral infections</span>. </span>Certain viruses can live in your body and cause active <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> when your immune system is weak. <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">Viral infections</span> that can happen with mycophenolic acid delayed-release tablets include: <dl>
<dt>â–ª</dt>
<dd><span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Shingles</span>, other <span class="product-label-link" type="condition" conceptid="435463" conceptname="Herpesvirus infection">herpes infections</span>, and cytomegalovirus (CMV). CMV can cause serious tissue and blood <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</dd>
<dt>â–ª</dt>
<dd>BK virus. BK virus can affect how your kidney works and cause your transplanted kidney to fail.</dd>
<dt>â–ª</dt>
<dd><span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> B and C viruses. <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> viruses can affect how your liver works. Talk to your doctor about how <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> viruses may affect you.</dd>
</dl>
</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">A brain <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> called <span class="product-label-link" type="condition" conceptid="433957" conceptname="Progressive multifocal leukoencephalopathy">Progressive Multifocal Leukoencephalopathy</span> (PML).</span> In some patients mycophenolic acid delayed-release tablets may cause an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> of the brain that may cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. You are at risk for this brain <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> because you have a weakened immune system. You should tell your healthcare provider right away if you have any of the following symptoms: <dl>
<dt>â–ª</dt>
<dd><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Weakness</span> on one side of the body</dd>
<dt>â–ª</dt>
<dd>You do not care about things that you usually care about (<span class="product-label-link" type="condition" conceptid="4071366" conceptname="Indifference">apathy</span>)</dd>
<dt>â–ª</dt>
<dd>You are <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confused</span> or have problems thinking</dd>
<dt>â–ª</dt>
<dd>You cannot control your muscles</dd>
</dl>
</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">Fungal infections</span>. </span>Yeast and other types of <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span> can happen with mycophenolic acid delayed-release tablets and cause serious tissue and blood <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. <span class="Bold">See "What are the possible side effects of mycophenolic acid delayed-release tablets?"</span>
</dd>
</dl>
</dd>
</dl>
<p><span class="Bold">Call your doctor right away if you have any of these signs and symptoms of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>:</span></p>
<dl>
<dt>o</dt>
<dd>Temperature of 100.5Â°F or greater</dd>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">Cold symptoms</span>, such as a <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">runny nose</span> or <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span></dd>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Flu symptoms</span>, such as an <span class="product-label-link" type="condition" conceptid="4012224" conceptname="Upset stomach">upset stomach</span>, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></dd>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="380733" conceptname="Otalgia">Earache</span> or <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></dd>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> during urination or you need to urinate often</dd>
<dt>o</dt>
<dd>White patches in the mouth or throat</dd>
<dt>o</dt>
<dd>Unexpected <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span> or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> </dd>
<dt>o</dt>
<dd>Cuts, scrapes, or incisions that are red, warm, and oozing pus<br><br>
</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">Increased risk of getting certain cancers. </span>People who take mycophenolic acid delayed-release tablets have a higher risk of getting <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>, and other cancers, especially skin cancer. Tell your doctor if you have: <dl>
<dt>o</dt>
<dd>unexplained <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span> that does not go away, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>, or lymph node <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span></dd>
<dt>o</dt>
<dd>a brown or black <span class="product-label-link" type="condition" conceptid="4316083" conceptname="Skin lesion">skin lesion</span> with uneven borders, or one part of the lesion does not look like other parts</dd>
<dt>o</dt>
<dd>a change in the size or color of a mole</dd>
<dt>o</dt>
<dd>a new <span class="product-label-link" type="condition" conceptid="4316083" conceptname="Skin lesion">skin lesion</span> or bump</dd>
<dt>o</dt>
<dd>any other changes to your health</dd>
</dl>
</dd>
</dl>
<p><span class="Bold">See the section "What are the possible side effects of mycophenolic acid delayed-release tablets?" for other serious side effects.</span></p>
<p><span class="Bold">What are mycophenolic acid delayed-release tablets?</span></p>
<p>Mycophenolic acid delayed-release tablets are a prescription medicine given to prevent rejection (antirejection medicine) in people who have received a kidney transplant. Rejection is when the body's immune system senses the new organ as "foreign" and attacks it.</p>
<p>Mycophenolic acid delayed-release tablets are used with other medicines containing cyclosporine (Sandimmune<span class="Sup">Â®</span>, Gengraf<span class="Sup">Â®</span>, and Neoral<span class="Sup">Â®</span>) and corticosteroids. </p>
<p>Mycophenolic acid delayed-release tablets can be used to prevent rejection in children who are 5 years or older and are stable after having a kidney transplant. It is not known if mycophenolic acid delayed-release tablets are safe and works in children younger than 5 years. It is not known how mycophenolic acid delayed-release tablets work in children who have just received a new kidney transplant.</p>
<p><span class="Bold">Who should not take mycophenolic acid delayed-release tablets?</span></p>
<p>Do not take mycophenolic acid delayed-release tablets if you are allergic to mycophenolic acid, mycophenolate sodium, mycophenolate mofetil, or any of the ingredients in mycophenolic acid delayed-release tablets. See the end of this Medication Guide for a complete list of ingredients in mycophenolic acid delayed-release tablets.</p>
<p><span class="Bold">What should I tell my doctor before I start taking mycophenolic acid delayed-release tablets?</span></p>
<p>Tell your healthcare provider about all of your medical conditions, including if you:</p>
<dl>
<dt>â€¢</dt>
<dd><span class="Bold">have any digestive problems, such as <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span></span></dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">plan to receive any vaccines. </span>You should not receive live vaccines while you take mycophenolic acid delayed-release tablets. Some vaccines may not work as well during treatment with mycophenolic acid delayed-release tablets. </dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">have Lesch-Nyhan or Kelley-Seegmiller syndrome or another rare inherited deficiency of hypoxanthine-guanine phosphoribosyl-transferase (HGPRT). </span>You should not take mycophenolic acid delayed-release tablets if you have one of these disorders. </dd>
<dt>â€¢</dt>
<dd><span class="Bold">are pregnant or planning to become pregnant. See "What is the most important information I should know about mycophenolic acid delayed-release tablets?"</span></dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">are breastfeeding or plan to breastfeed.</span> It is not known if mycophenolic acid passes into breast milk. You and your doctor will decide if you will take mycophenolic acid delayed-release tablets or breastfeed.</dd>
</dl>
<p><span class="Bold">Tell your doctor about all the medicines you take, including prescription and nonprescription medicines, vitamins, and herbal supplements. </span></p>
<p>Some medicines may affect the way mycophenolic acid delayed-release tablets work and mycophenolic acid delayed-release tablets may affect how some medicines work. Especially tell your doctor if you take:</p>
<dl>
<dt>â€¢</dt>
<dd>birth control pills (oral contraceptives). <span class="Bold">See "What is the most important information I should know about mycophenolic acid delayed-release tablets?"</span>
</dd>
<dt>â€¢</dt>
<dd>antacids that contain aluminum or magnesium. Mycophenolic acid delayed-release tablets and antacids should not be taken at the same time.</dd>
<dt>â€¢</dt>
<dd>acyclovir (Zovirax<span class="Sup">Â®</span>), Â Ganciclovir (Cytovene<span class="Sup">Â®</span> IV, and Valcyte<span class="Sup">Â®</span>)</dd>
<dt>â€¢</dt>
<dd>azathioprine (Azasan<span class="Sup">Â®</span>, Imuran<span class="Sup">Â®</span>)</dd>
<dt>â€¢</dt>
<dd>cholestyramine (Questran<span class="Sup">Â®</span> Light, Questran<span class="Sup">Â®</span>, Locholest Light, Prevalite<span class="Sup">Â®</span>)</dd>
</dl>
<p>Know the medicines you take. Keep a list of your medicines with you to show your healthcare provider and pharmacist when you get a new medicine. Do not take any new medicine without talking to your doctor.</p>
<p><span class="Bold">How should I take mycophenolic acid delayed-release tablets?</span></p>
<dl>
<dt>â€¢</dt>
<dd>Take mycophenolic acid delayed-release tablets exactly as prescribed. Your healthcare provider will tell you how much mycophenolic acid delayed-release tablets to take.</dd>
<dt>â€¢</dt>
<dd>Do not stop taking or change your dose of mycophenolic acid delayed-release tablets without talking to your healthcare provider. </dd>
<dt>â€¢</dt>
<dd>Take mycophenolic acid delayed-release tablets on an empty stomach, either 1 hour before or 2 hours after a meal.</dd>
<dt>â€¢</dt>
<dd>Swallow mycophenolic acid delayed-release tablets whole. Do not crush, chew, or cut mycophenolic acid delayed-release tablets. The mycophenolic acid delayed-release tablets have a coating so that the medicine will pass through your stomach and dissolve in your intestine. <dl>
<dt>o</dt>
<dd>
<span class="Bold">If you forget to take mycophenolic acid delayed-release tablets, </span>take it as soon as you remember and then take your next dose at its regular time. If it is almost time for your next dose, skip the missed dose. Do not take two doses at the same time. Call your doctor or pharmacist if you are not sure what to do.</dd>
<dt>o</dt>
<dd>
<span class="Bold">If you take more than the prescribed dose of mycophenolic acid delayed-release tablets, </span>call your doctor right away.</dd>
<dt>o</dt>
<dd>
<span class="Bold">Do not change (substitute) between using mycophenolic acid delayed-release tablets and mycophenolate mofetil tablets, capsules, or oral suspension for one another unless your healthcare provider tells you to. </span>These medicines are absorbed differently. This may affect the amount of medicine in your blood.</dd>
<dt>o</dt>
<dd>Be sure to keep all appointments at your transplant clinic. During these visits, your doctor may perform regular blood tests.</dd>
</dl>
</dd>
</dl>
<p><span class="Bold">What should I avoid while taking mycophenolic acid delayed-release tablets?</span></p>
<p><span class="Bold">Avoid pregnancy. </span>See<span class="Bold"> "What is the most important information I should know about mycophenolic acid delayed-release tablets?"</span></p>
<dl>
<dt>â€¢</dt>
<dd>Limit the amount of time you spend in sunlight. Avoid using tanning beds and sunlamps. People who take mycophenolic acid delayed-release tablets have a higher risk of getting skin cancer. <span class="Bold">See "What is the most important information I should know about mycophenolic acid delayed-release tablets?" </span>Wear protective clothing when you are in the sun and use a sunscreen with a high sun protection factor (SPF 30 and above). This is especially important if your skin is fair (light colored) or you have a family history of skin cancer.</dd>
<dt>â€¢</dt>
<dd>Elderly patients 65 years of age or older may have more side effects with mycophenolic acid delayed-release tablets because of a weaker immune system.</dd>
</dl>
<p><span class="Bold">What are the possible side effects of mycophenolic acid delayed-release tablets?</span></p>
<p><span class="Bold">Mycophenolic acid delayed-release tablets can cause serious side effects.</span></p>
<p><span class="Bold">See "What is the most important information I should know about mycophenolic acid delayed-release tablets?"</span></p>
<p>Stomach and intestinal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> can happen in people who take mycophenolic acid delayed-release tablets. <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> can be severe and you may have to be hospitalized for treatment.</p>
<p>The most common side effects of taking mycophenolic acid delayed-release tablets include:</p>
<p>In people with a new transplant:</p>
<dl>
<dt>â€¢</dt>
<dd>low blood cell counts <dl>
<dt>o</dt>
<dd>red blood cells</dd>
<dt>o</dt>
<dd>white blood cells</dd>
<dt>o</dt>
<dd>platelets</dd>
</dl>
</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4152197" conceptname="Stomach ache">stomach upset</span></dd>
</dl>
<p>In people who take mycophenolic acid delayed-release tablets for a long time (long-term) after transplant:</p>
<dl>
<dt>â€¢</dt>
<dd>low blood cell counts <dl>
<dt>o</dt>
<dd>red blood cells</dd>
<dt>o</dt>
<dd>white blood cells</dd>
</dl>
</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span></dd>
</dl>
<p>Your healthcare provider will do blood tests before you start taking mycophenolic acid delayed-release tablets and during treatment with mycophenolic acid delayed-release tablets to check your blood cell counts. Tell your healthcare provider right away if you have any signs of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> <span class="Bold">(see </span>"<span class="Bold">What is the most important information I should know about mycophenolic acid delayed- release tablets?"), </span>or any unexpected <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span> or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Also, tell your healthcare provider if you have unusual <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, or <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span>.</p>
<p>These are not all the possible side effects of mycophenolic acid delayed-release tablets. Your healthcare provider may be able to help you manage these side effects. </p>
<p>Call your doctor for medical advice about side effects. </p>
<p>You may report side effects to </p>
<dl>
<dt>â€¢</dt>
<dd>FDA MedWatch at 1-800-FDA-1088 or </dd>
<dt>â€¢</dt>
<dd>Apotex Corp. at 1-800-706-5575.</dd>
</dl>
<p><span class="Bold">How should I store mycophenolic acid delayed-release tablets?</span></p>
<dl>
<dt>â€¢</dt>
<dd>Store mycophenolic acid delayed-release tablets at room temperature, 59Â° to 86Â°F (15Â° to 30Â°C). Mycophenolic acid delayed- release tablets do not need to be refrigerated.</dd>
<dt>â€¢</dt>
<dd>Store mycophenolic acid delayed-release tablets in a dry place.</dd>
<dt>â€¢</dt>
<dd><span class="Bold">Keep mycophenolic acid delayed-release tablets and all medicines out of the reach of children.</span></dd>
</dl>
<p><span class="Bold">General information about mycophenolic acid delayed-release tablets</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use mycophenolic acid delayed-release tablets for a condition for which it was not prescribed. Do not give mycophenolic acid delayed-release tablets to other people, even if they have the same symptoms you have. It may harm them.</p>
<p>This Medication Guide summarizes the most important information about mycophenolic acid delayed-release tablets. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about mycophenolic acid delayed-release tablets that is written for healthcare professionals. You can also call Apotex Corp. at 1-800-706-5575. </p>
<p><span class="Bold">What are the ingredients in mycophenolic acid delayed-release tablets?</span></p>
<p><span class="Bold">Active ingredient: </span>mycophenolic acid (as mycophenolate sodium)</p>
<p><span class="Bold">Inactive ingredients: </span>methylcellulose, sodium lauryl sulfate, stearic acid, colloidal silicon dioxide, hypromellose and polyethylene glycol. The enteric coating of the tablet consists of triethyl citrate, talc, titanium dioxide, yellow ferric oxide (180 mg and 360 mg), indigotine al lake (180 mg), methacrylic acid and ethyl acrylate copolymer dispersion, and red ferric oxide (360 mg).</p>
<p><span class="Bold">This Medication Guide has been approved by the U.S. Food and Drug Administration.</span></p>
<p>All registered trademarks in this document are the property of their respective owners. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="_921bbded-78ee-2ec6-98e4-9f878b33eeea"></a><a name="section-16.1"></a><p></p>
<p class="First">Packaged and Distributed by:<br><span class="Bold">American Health Packaging <br></span>Columbus, OH 43217</p>
<p>8290721/1114</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="_fe4c74a1-87b7-e583-e5f5-06f3b7a30fa5"></a><a name="section-17"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL â€“ 180 mg</h1>
<div class="Figure">
<a name="id-1452465538"></a><img alt="Mycophenolic Acid Delayed Release Tablets (as mycophenolate sodium) 180 mg label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=26b31126-4262-4a15-8a16-234c86763176&amp;name=Mycophenolic%20Acid%20Delayed%20Release%20Tablets%20(as%20mycophenolate%20sodium)%20180%20mg%20label.jpg">
</div>
<p class="First"><span class="Bold">NDC 68084-907-21</span></p>
<p><span class="Bold">Mycophenolic Acid*<br>Delayed Release Tablets<br>* as mycophenolate sodium</span></p>
<p><span class="Bold">180 mg</span></p>
<p><span class="Bold">30 Tablets (3 Ã— 10)</span></p>
<p><span class="Bold">PHARMACIST: </span>Dispense with the accompanying<br>Medication Guide to each patient</p>
<p><span class="Bold">Each Tablet Contains:<br></span>Mycophenolic Acidâ€¦â€¦ â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦. 180 mg<br>Take on empty stomach, 1 hour before or 2 hours after a meal.<br>Do not crush, chew, or cut tablet.<br><span class="Bold">Usual Dosage:</span> See package insert for full prescribing information. <br><span class="Bold">Store</span> at 20Âº to 25ÂºC (68Âº to 77ÂºF); excursions permitted to 15Âº to <br>30ÂºC (59Âº to 86ÂºF) [see USP Controlled Room Temperature].<br>Protect from moisture.<br><span class="Bold">Keep this and all drugs out of reach of children.<br>Rx Only<br></span>The drug product contained in this package is from <br>NDC # 60505-2965, Apotex Corp.<br>Packaged and Distributed by: <br>American Health Packaging<br>Columbus, Ohio 43217</p>
<p>090721<br>Rev. 11/2014</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="_10293cab-75be-77e1-19e0-327a0508f754"></a><a name="section-18"></a><p></p>
<h1> PRINCIPAL DISPLAY PANEL â€“ 360 mg</h1>
<div class="Figure">
<a name="id1857766830"></a><img alt="Mycophenolic Acid Delayed Release Tablets (as mycophenolate sodium) 360 mg label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=26b31126-4262-4a15-8a16-234c86763176&amp;name=Mycophenolic%20Acid%20Delayed%20Release%20Tablets%20(as%20mycophenolate%20sodium)%20360%20mg%20label.jpg">
</div>
<p class="First"><span class="Bold">NDC 68084-918-25</span></p>
<p><span class="Bold">Mycophenolic Acid*<br>Delayed Release Tablets<br>* as mycophenolate sodium</span></p>
<p><span class="Bold">360 mg</span></p>
<p><span class="Bold">30 Tablets (5 Ã— 6)</span></p>
<p><span class="Bold">PHARMACIST: </span>Dispense with the accompanying<br>Medication Guide to each patient</p>
<p><span class="Bold">Each Tablet Contains:<br></span>Mycophenolic Acidâ€¦â€¦ â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦. 360 mg<br>Take on empty stomach, 1 hour before or 2 hours <br>after a meal. Do not crush, chew, or cut tablet.</p>
<p><span class="Bold">Usual Dosage:</span> See package insert for full prescribing <br>information. </p>
<p><span class="Bold">Store</span> at 20Âº to 25ÂºC (68Âº to 77ÂºF); excursions permitted <br>to 15Âº to 30ÂºC (59Âº to 86ÂºF) [see USP Controlled Room <br>Temperature]. Protect from moisture.</p>
<p><span class="Bold">Keep this and all drugs out of reach of children.</span></p>
<p><span class="Bold">Rx Only</span></p>
<p>The drug product contained in this package is from <br>NDC # 60505-2966, Apotex Corp.</p>
<p>Packaged and Distributed by: <br>American Health Packaging<br>Columbus, Ohio 43217</p>
<p>091825<br>Rev. 11/2014</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MYCOPHENOLIC ACIDÂ 		
					</strong><br><span class="contentTableReg">mycophenolic acid tablet, delayed release</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:68084-907(NDC:60505-2965)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>MYCOPHENOLATE SODIUM</strong> (mycophenolic acid) </td>
<td class="formItem">mycophenolic acid</td>
<td class="formItem">180Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>METHYLCELLULOSE (400 MPA.S)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STEARIC ACID</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOLS</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TRIETHYL CITRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">GREEN</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">9mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">MYC;180;APO</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:68084-907-21</td>
<td class="formItem">30  in 1 BOX, UNIT-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:68084-907-11</td>
<td class="formItem">1  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA091558</td>
<td class="formItem">01/15/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MYCOPHENOLIC ACIDÂ 		
					</strong><br><span class="contentTableReg">mycophenolic acid tablet, delayed release</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:68084-918(NDC:60505-2966)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>MYCOPHENOLATE SODIUM</strong> (mycophenolic acid) </td>
<td class="formItem">mycophenolic acid</td>
<td class="formItem">360Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>METHYLCELLULOSE (400 MPA.S)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STEARIC ACID</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOLS</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TRIETHYL CITRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">PINK</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">15mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">APO;MYC;360</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:68084-918-25</td>
<td class="formItem">30  in 1 BOX, UNIT-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:68084-918-95</td>
<td class="formItem">1  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA091558</td>
<td class="formItem">01/15/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>American Health Packaging
							(007914906)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">American Health Packaging</td>
<td class="formItem"></td>
<td class="formItem">929561009</td>
<td class="formItem">REPACK(68084-907, 68084-918)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 1/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>cf2f4d1f-b851-4075-860f-da5f1932db4f</div>
<div>Set id: 26b31126-4262-4a15-8a16-234c86763176</div>
<div>Version: 1</div>
<div>Effective Time: 20150114</div>
</div>
</div>Â <div class="DistributorName">American Health Packaging</div></p>
</body></html>
